Welcome To Q Research Bunker (QRB) General

We hold these truths to be self-evident: that all men are created equal; that they are endowed by their Creator with certain unalienable rights; that among these are life, liberty, and the pursuit of happiness.

We are researchers who deal in open-source information, reasoned argument, and dank memes. We do battle in the sphere of ideas and ideas only. We neither need nor condone the use of force in our work here.

VINCIT OMNIA VERITAS

SEMPER FIDELIS

WWG1WGA

Q Proofs & Welcome

Welcome to Q Research (README FIRST, THEN PROCEED TO LURK) https://8kun.top/qresearch/welcome.html

THE Q MOVEMENT IS ABOUT TRUMPING THE ESTABLISHMENT - https://www.tube.com/channel/UCDFe_yKnRf4XM7W_sWbcxtw

Q: The Basics - An Introduction to Q and the Great Awakening

PDF & PICS Archive >>>/comms/3196

100+ Q Proof Graphics qproofs.com

QResearch Welcome Page https://8kun.top/qresearch/welcome.html

8kun FAQs https://8kun.top/faq.html

How to screenshot, insert MP4's, embed videos (YT & Twitter) >>>/comms/9658

Q's Latest Posts

Tuesday 12.08.2020

>>>/qresearch/11953143 ————————————–——– We're Not Gonna Take It (CAP: >>11953295)

Q's Private Board

>>>/projectDcomms/ | Q's Trip-code Q !!Hs1Jq13jV6

All Q's posts

Archived at - qanon.app (qanon.pub) , qmap.pub , qanon.news , qposts.online

Onion Link

Access through Tor: http://jthnx5wyvjvzsxtu.onion/qrb/catalog.html

Dealing with Clowns & Shills

How To Quickly Spot A Clown >>78126 (https://pastebin.com/PpctCf9z)

NEWFAGS TO QRB BOARD

QRB content policy HERE: >>57466, >>61742, >>62044, >>69762 UPDATE

Plz see BV-bakers in QRB General to make a new thread >>77874 UPDATE

Globals

HELP WANTED: If you want to learn to bake let us know

>>77592 Rusty/Q thread NEW

>>74385 BITCHUTE embedding now enabled in 8 new

>>71855 Archive QR deletions here

>>69095 Guidelines on CP, what to report in addition to illegal images

Notables

are not endorsements

#482

>>79236, >>79260 CodeMonkeyZ BOMBSHELL- Dominion Whistleblower Speaks Out – Releases Admin Password Proving Remote Access –VIDEO

>>79238 President Biden calls on New York Governor Cuomo to resign

>>79245 House Republicans protest the mask mandate in the Senate

>>79246 Italy parliament in an uproar over "Green Pass" vax passports

>>79247 Reporter to Biden - why are the unvaxxed allowed to enter the country?

>>79248 FINAL LIST OF STATE CHATS - Election Audits

>>79249, >>79254 The Five Doctors: Dr. Lee Merritt, Dr. Christiane Northrup, Dr. Carrie Madje, Dr. Sherri Tenpenny, and Dr. Larry Palevsky

>>79251 NY VACCINE PASSPORT IS THE HILL TO DIE ON

>>79252 The Atlantic thinks unvaxxed people should be on NO-FLY list ("they want us dead")

>>79253 Army gives Pfizer $3.5B contract to make 500 million COVID vaccine doses

>>79255 Giuliani: The Covid Rich Get Richer

>>79256 Giluliani: All Lies Will Be Revealed

>>79257 About half of all new covid cases are vaxxed (UK)

>>79258 Iceland and Singapore lift all coronavirus restrictions

>>79259 Upcoming events: the heat is being turned up

>>79261 McCloskeys pardoned by Missouri Governor over last year's viral incident

>>79268 #482

#481

>>79169, >>79194, >>79202, >>79204 Eyez on the skyz

>>79216 Chinese national plead guilty in money laundering scheme connected to El Chapo’s cartel

>>79215 Tyson Foods will require all U.S. employees to be vaccinated by November

>>79210, >>79211 LATEST FROM ARCHBISHOP VIGANO ON THE VACCINES AS CHILD SACRIFICE

>>79203 Devolution - Part 7 - Foreign Interference

>>79201 Biden Infrastructure Bill Mandates Drunk-Driver Detector Surveillance Systems For New Cars

>>79200 Eric Rosenbach, CENTER of the electronic voting fraud

>>79198 VIRGINIA! multiple Counties where fraudis almost certain, Audits will prove

>>79189 45: congrats to Carey in Ohio win

>>79182 massive exercise will span 17 time zones with sailors and Marines in the U.S., Africa, Europe and the Pacific joining.

>>79178, >>79180, >>79184, >>79195 CM: Remote Access?

>>79177, >>79179, >>79183 U.S. Banking System Has a $168 Trillion Nightmare Looming. It Was Ignored in Written Testimony for Today’s Senate Banking Hearing

>>79176 Law of War guy

>>79174 GOP Senator Introduces Bill To Require States That Mandate Vaccine Passports To Also Mandate Voter ID

>>79173 ELITE GOVENERS AND CUOMO COMMS FROM Q

>>79172, >>79196, >>79197, >>79214 PROMINENT DEMS CALLING FOR @NYGovCuomo TO RESIGN:/RudyG rebutts

>>79171 FDA Authorizes Antibody Cocktail as COVID-19 Prevention Treatment

>>79170 Lockheed Martin CFO Abruptly Retires For ‘Personal Reasons’

>>79168 Virginia Group Looks to Recall Radical Soros-Backed Prosecutors

>>79167 Mr. Cooper Group, Inc. sold by Kohlberg, Kravis, Roberts & Co.: $368.18m-Aug 2

>>79162 Germany preppin lockdown

>>79161 CDC has no authority to issue eviction mandates

>>79160, >>79166 ANTIFA CHAT LOGS

>>79154 America’s Tamyra Mensah-Stock won gold at Tokyo in wrestling: She's Awesome!

>>79218 #481

#480

>>79077, >>79088, >>79103, >>79108, >>79112, >>79124, >>79130, >>79139 Tongue Out Tuesday planefaggin

>>79142, >>79144 Pompeo/Q/Cuba

>>79136 After Claiming Hands Tied, Biden Admin To Issue 'Targeted' Eviction Ban

>>79131, >>79132 45 WH on road to financial ruin, Seth Keshel

>>79129 Is it Huma?

>>79122 Maggie on Cuomo losing union support

>>79119 US household debt surged to nearly $15T in second quarter, a new record

>>79117 Airports From Nantucket To California Suffer Jet Fuel Shortages

>>79115, >>79120, >>79121 WHY IS THIS PICTURE INCLUDED IN THE GOVERNOR’S RESPONSE???

>>79111, >>79113 Cuomo released his response on his webpage.

>>79105 Book is being thrown/AZ audit

>>79104 mail in recall kekked

>>79096 Pentagon reopens following shooting, stabbing incident, no deets

>>79093, >>79094 Dr. Shiva Discovers Existence of the Secretive Long Fuse Report

>>79092 1:12 Delta/Q

>>79089, >>79095, >>79140 Calls for Cuomo to resign

>>79086 The USA is not the only Country in the World using Dominion / Smartmatic voting machines.

>>79082 Scientific Journal Paper Suggests Making It A ‘Federal Hate Crime’ To Criticize Fauci.

>>79080 U.S. overnight repo rate elevated after Monday's funding pressure

>>79079 Absolute Proof vid

>>79145 #480

#479

>>79026 Tungz Out Tuesday planefaggin

>>79065 EMA Vaxzevria / AstraZeneca - Produkt information

>>79064 Microsoft to Require Vaccinations to Enter U.S. Offices

>>79062 @AFResearchLab is building an advanced high-power microwave weapon system

>>79061, >>79063 Colorado Sec. of State Moves to Eliminate Signature Verification, ‘Protect’ Dead Voters and Put Gag Order on Poll Workers

>>79060 Titanic news today

>>79058 The #USCG released an updated Cyber Strategic Outlook today to address the rising threat of cyber-attacks against critical maritime systems

>>79053 This is at least the 2nd time the IG found a senior FBI official "violated federal regulations" accepting gifts from journalists

>>79052 Can we just take a moment to appreciate just how powerful CM's social influence has become to......................

>>79048 Japan government starts to 'name and shame' quarantine rule-breakers

>>79046, >>79047, >>79049, >>79051 CORONA is America's first successful photographic reconnaissance satellite #HISTINT #Museum

>>79044, >>79045 The Deep Rig is now FREE to watch, gotta sign in though

>>79043 Ever Given: Cargo ship that blocked Suez Canal arrives in Felixstowe

>>79035 Duolingo, Inc sold by CapitalG (formerly Google Capital): $36.32m-July 30

>>79034 ECW: Iran's drone attack killed two European civilians. That's a terrorist attack.

>>79032 If the AZGOP solicited donations for the Maricopa forensic audit, why didnt they send money?

>>79031 @USArmy Increasing Soldier #lethality!

>>79029, >>79030 Economist chooses Satan to chair their meetings

>>79024 4th 1/6 suicide reported was on July 10

>>79022 NYC to Require Citizens to Show Vaccine Papers

>>79020, >>79021, >>79027 Moar Pentagon lockdown

>>79018, >>79019 ,>>79041 CM vid, Katie Hobbs has the password, so does CM

>>79017, >>79028 from 2 then to 4 ships off the coast of the UAE are broadcasting warnings that they have lost control of their steering

>>79016 Pompeo/Q For God and Country

>>79015, >>79039 NY AG finds Cuomo guilty

>>79010 Florida takes action against Ben & Jerry's parent company amid fight over Israel

>>79001, >>79006 666 skank

>>79066 #479

Previously Collected Notables:

>>78736 #475, >>78825 #476, >>78904 #477, >>78989 #478

>>78069 #469, >>78199 #470, >>78333 #471, >>78459 #472, >>78517 #473, >>78631 #474

>>77465 #463, >>77547 #464, >>77647 #465, >>77724 #466, >>77839 #467, >>77985 #468

QRB notables archived here >>>/qrb/9528

Notables aggregator https://wearethene.ws

Notables aggregator https://qnotables.com

Meme Ammo

>>>/qrmemes/ One-stop Meme Board, organized by topic

>>>/qrb/57489 Digital Camo Thread Archive

>>>/qrmemes/606 Meme Camo Thread

Dedicated Research Threads

>>>/qresearch/14121360 Clockwork Qrange #13

>>>/qrb/13005 Planefagging 101 Q&A

>>>/qrb/42185 Boatfagging Q&A

>>>/qrb/22979 Information Warfare II

>>>/comms/12299 Oregon, Washington, I-5 Corridor: Turn the Tide

>>>/comms/26525 Exposing Media Lies about Q: Post Attacks Against Q here

International Q Research Threads

>>>/qresearch/14019901 ————————————–——– Australia #17

>>>/qresearch/13323637 ————————————–——– Balkan #8

>>>/qresearch/13167439 ————————————–——– Brazil #2

>>>/qresearch/14080238 ————————————–——– Canada #22

>>>/qresearch/13269960 ————————————–——– France #4

>>>/qresearch/14166186 ————————————–——– Germany #84

>>>/qresearch/13187313 ————————————–——– Italia #2

>>>/qresearch/13226402 ————————————–——– Japan #2

>>>/qresearch/13410974 ————————————–——– Mexico #3

>>>/qresearch/13105482 ————————————–——– Nederland #6

>>>/qresearch/13163282 ————————————–——– New Zealand #8

>>>/qresearch/13163911 ————————————–——– Nordic #3

>>>/qresearch/13163805 ————————————–——– Russia #2

>>>/qresearch/13163650 ————————————–——– Scotland #4

>>>/qresearch/14081815 ————————————–——– South Africa #6

>>>/qresearch/13991348 ————————————–——– UK #40

Q Proofs & Posts

Q Proofs Threads Proofs of Q's Validity >>>/qresearch/6156082

Book of Q Proofs https://mega.nz/#F!afISyCoY!6N1lY_fcYFOz4OQpT82p2w - https://bookofqproofs.wordpress.com/

Storm is here Q Posts Q&A & all images bu docs.google.com/spreadsheets/d/1Efm2AcuMJ7whuuB6T7ouOIwrE_9S-1vDJLAXIVPZU2g/

Q & POTUS timestamps docs.google.com/spreadsheets/d/1OqTR0hPipmL9NE4u_JAzBiWXov3YYOIZIw6nPe3t4wo/

Q Happenings Calendar

Submit an event here https://teamup.com/ks8x4ixptej432xt2a

Main Calendar URL https://dark-to-light.org/calendar/

Sealed Indictments

Sealed Indictment Master https://docs.google.com/spreadsheets/d/1kVQwX9l9HJ5F76x05ic_YnU_Z5yiVS96LbzAOP66EzA/edit#gid=1525422677

Sealed Indictment Master Files Backup https://drive.google.com/open?id=1iBS4WgngH8u8-wAqhehRIWCVBQKD8-5Y

Searchable Indictment Map w/dockets, links & more https://bad-boys.us/

Resignations

All Resignations Website https://www.resignation.info

All Posts Search Tool https://qresear.ch

Q Graphics

Q Graphics all in GMT >>>/qrb/57490, #001 and scroll down >>>/comms/283

Original, full-size images Q has posted postimg.cc/gallery/29wdmgyze/

Tweet Tools

All My Tweets - Archive/Scan any Twatter account in text form www.allmytweets.net/

Twitter Video Downloader twittervideodownloader.com/

Deleted Trump Tweets factba.se/topic/deleted-tweets

Trump Tweet Archive trumptwitterarchive.com

Archives & Archivers

Archivers for Firefox, Opera & Webpage >>57496

QRB General Archive archive8kun.top/qrb/archive/index.html

(only activated for breads fallen off the catalog)

QR - MasterArchivist masterarchivist.github.io/qarchives/

QR - MasterArchivist (supplement) (main spreadsheet, 2nd tab, labeled)

https://docs.google.com/spreadsheets/d/1M2AzhZKh2PjL7L7GVPN42Em0hZXKWMdhGnj59ZQ3YcQ/

QR - GermanArchiveAnon mega.nz/folder/LPZxEIYJ#N5JwCNoxOxOtAoErKdUgvw

Wayback Machine for old archived websites https://web.archive.org

Webpage Archiver: http://archive.md/

Other Tools

500 videos from the Capital on Jan 6' >>67804 new

Advanced Google Search Operators ahrefs.com/blog/google-advanced-search-operators/

Biden's destruction of America - first 100 days >>58856

Commercial Aviation Incident List avherald.com

Criminal Cases Database https://www.justice.gov/usao/find-r-united-states-attorney

DMCA takedown notice or abuse report reporting@isitwetyet.com.

Federal Judicial Court Dataset from 93 Federal Districts - Searchable db '''bad-boys.us/

Federal Procurement Data System www.fpds.gov/fpdsng_cms/index.php/en/

Hosts File (DNS), How to Edit >>>/comms/4396

Hussein WH visitor list qest.us/obamavisitors

Legal News www.justice.gov/usao/pressreleases

Links to Alt-Media (Contacts, Websites) >>51758

Q Boards/Sites >>58867

Qcode Guide to Abbreviations pastebin.com/UhK5tkgb

Research Section Backup >>>/comms/220 (updated 1.12.19)

Reverse image search to sauce https://tineye.com/

Stock Movement Scraper qest.us (for seeing LARGE movements of $)

Staff Notes

BO changes/board updates >>57468, >>57469, >>57470, >>57471, >>57472, >>57473

Notables - plz list more often at end of bread >>57493

Passwords in fullchan.net - do not use >>57494

QRB baking - watch for a lag >>57495

QRB content policy >>57466

Wearethene.ws formatting >>57477, >>57480, >>57481, >>57482, >>57483, >>57484, >>57485, >>57486, >>57481, >>57484

Learn To Bake!

Quick Pic Bakes & E-bake instructions >>57491, https://pastebin.com/aY5LyDPY, >>>/comms/9252

Resources from last LIVE Baking Class #39 >>>/comms/40980 (step by step baking instructions)

Baker Tools - several versions >>58368

How to format multi-page notables https://qanonbin.com/paste/0kIGTHWjd

Tips on Notables for Bakers >>>/comms/41080

Iwo Jima flag on YouTube for TOR posting https://tu.be/9E3uBWn7e8U

dough

https://fullchan.net/?71c865d094f979b7#Eu2d49VNdoqEaGPFBE4HTxZRKirS3JgEseoUTdRMcgHZ

https://controlc.com/4f04ac2b

All Lies Will Be Revealed - Rudy Giuliani

This bread is dedicated to RUDY GIULIANI - the man who SAVED NYC

To his rightful redemption and future success!

baker stepping down

Goodnight latenighters

See u tomorrow

o7

>>79274

nite frby n ty fer the bred.

morn'n baker czech'n in

>>79278

>morn'n baker czech'n in

yay!

>>79279

morn'n and habby wednesday.

>>79279

[their] day is coming.

justice will prevail and they definitely won't be able to walk down the street when it all shakes out.

nothing fucky going on here that's fer sure..

A new Emerson College poll shows a statistical tie between likely voters who favor removing Gov. Gavin Newsom (46%) in the Sep. 14 recall, and those who favor retaining him (48%). The poll, conducted July 30-August 1, has a margin of error of 3%.

Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

https://www.breitbart.com/podcast/2021/08/03/vote-to-remove-gavin-newsom-within-margin-of-error-hispanics-favor-recall/

XOXO

If Jim and CM could get more eyes in here, we could get back on track. In a short while I'll be getting a new computer. Needed. At that point I will agree to bake for the first time after digging since Nov '17 (and previously on my own for years). Anon made a promise to self to stay away from the kitchen. May be willing to step up soon.

>>79284

anons will migrate. it should be organic. all guud.

>>79278

mornin wakers

howza

rainin muh westie

at least cooler

>>79286

yo bro.

cloudy here. wind pickn up too.

rough irl for me today. sorry to dump on you, but from 11 on i am wurkfagg'n.

US Customs Border Patrol MQ9 Reaper Drone running the border CA-AZ

SAM039 USAF G5 departed JBA

This AC wuz SAM014 yesterday and went to Peterson AFB for a quick ground stop after an overnight at Richmond Int'l

morning

>>79288

dem 8s

morn'n gb. habby wenzday

>>79287

that's why I'm here

if I can't be right here at that moment just drop em

I'll pick em up

no worries

>>79288

mornin G

rollin dubs first thing

gonna be a guud day

howza

>>79290

oldest got in some trubble yesterday.

big trubble. wakes no habby rn

>>79289

o7

>>79290

ok

a little bettah been going on for over a week like dis

Hopefully get some relief soon.

Treasury To Start Reducing Bond Auction Sizes As Soon As November

Heading into today's quarterly refunding announcement, the bond market was on edge over the (low) possibility widely discussed on sellside desks, that the Treasury could cut trim coupon auction sizes in the next few months to coincide with the Fed's tapering as the Treasury's funding needs have gradually emerged to be less than expected thanks to higher than expected tax revenues. In fact, according to some the drop in yields in recent weeks has been not due to the ongoing monster squeeze but due to expectations that there will be less TSY supply than demand.

So when the Treasury released its latest refunding statement (whose highlights hit about 10 mins early after some newswire broke the embargo), battered TSY bears breathed a sigh of relief because the Treasury said that contrary growing expectations, it "does not anticipate making any changes to nominal coupon and FRN auction sizes over the next quarter." Here is the proposed treasury issuance scheduled for Q3-see cap#2

However, in line with expectations, "continuing current issuance sizes and patterns may provide more borrowing capacity than is needed to address borrowing needs over the intermediate-to-long term." As a result, the "Treasury will continue to engage with a variety of market participants to better understand the supply and demand dynamics for existing securities, with an expectation of announcing an initial set of auction size reductions as soon as the November refunding announcement" which is also in line with what most Primary Dealers had expected (among the 24 primary dealers in U.S. government securities, just three expected smaller auctions during the August-to-October quarter, with many more seeing an announcement in November). In other words, shortly after the Fed's taper announcement at or just after Jackson Hole, the Treasury will follow up with an issuance cut of its own.

So if no changes in coupon sizes, will Bill issuance at least shrink? You bet: as the Treasury added, "seasonal or unexpected variations in borrowing needs over the next quarter is to be met by changes in bill auction sizes and Cash Management Bills (CMBs)." Additionally, the Treasury will end weekly issuance of 6-week CMBs later this month: (cause why would you buy those if you can park yer 'unwanted cash' at the FRBNY for 5 basis points guaranteed-they know this)

Also of note, now that the US has triggered the debt ceiling extension measures which have an impact on how much cash the Treasury can hold at the current moment ($450BN), the Treasury said that it is unsure how long extraordinary measures put in place due to the debt ceiling will last: As Secretary Yellen recently outlined in a July 23 letter to Congress, the period of time that extraordinary measures may last is subject to considerable uncertainty due to a variety of factors, including the challenges of forecasting the payments and receipts of the U.S. government months into the future, exacerbated by the heightened uncertainty in payments and receipts related to the economic impact of the pandemic. Given this, Treasury is not able to currently provide a specific estimate of how long extraordinary measures will last.

While it was of secondary importance, the Treasury also revealed the details of next week's auctions a/k/a the quarterly refunding offering, which was in line with expectations. Specifically, the Treasury will offer $126 billion of Treasuries to refund $58.6 billion of Treasury notes and bonds maturing on August 15, 2021. This issuance will raise new cash of approximately $67.4 billion. The securities are:

*A 3-year note in the amount of $58 billion, as expected

*A 10-year note in the amount of $41 billion, as expected

*A 30-year bond in the amount of $27 billion, as expected

moar

https://www.zerohedge.com/markets/treasury-start-reducing-bond-auction-sizes-soon-november

>>79292

>>79292

oh wakers

prayers yo

muh youngest, greys, wrinkles, tude

no kek

gotz ears if ya need em

>>79293

glad yo adam cage feelin betters

sux when it hurts to breathe or move or sit still

>>79295

thx bro

Fed's Clarida backs raising interest rates in 2023

The Federal Reserve should be in the position to begin raising interest rates in 2023, Fed Vice Chair Richard Clarida said on Wednesday, as he predicted the U.S. economy remains on track to meet the central bank’s employment and inflation goals.

“I believe that these ... necessary conditions for raising the target range for the federal funds rate will have been met by year-end 2022,” Clarida said in prepared remarks for a webcast discussion hosted by the Peterson Institute for International Economics. “Commencing policy normalization in 2023 would, under these conditions, be entirely consistent with our new flexible average inflation targeting framework.” Fed officials hold a range of views on when to begin raising the central bank’s benchmark overnight interest rate, which is currently near zero, but several of them have sped up their forecast timeline for doing so. According to quarterly projections released at the Fed’s June policy meeting, thirteen of 18 policymakers now see rates higher in 2023, with seven of them penciling in a rates ‘lift-off’ as soon as next year.

Inflation continues to run well above the Fed’s 2% flexible goal, but there are still 6.8 million fewer people employed than just before the onset of the coronavirus pandemic. Fed Chair Jerome Powell said last week that the jobs recovery was still “a ways off” from where it needed to be to raise interest rates but acknowledged the central bank was monitoring inflation carefully to make sure the current overshoot is not persistent. In his prepared remarks on Wednesday, Clarida said he expects the Fed’s full employment mandate to have been met by the end of 2022. While he still expects current high inflation readings to moderate, if the Fed’s preferred inflation gauge comes in above 3% this year, he also said he would consider that more than a moderate overshoot of the Fed’s inflation goal. “I believe that the risks to my outlook for inflation are to the upside,” Clarida said.

He also noted the rapid spread of the Delta variant of the coronavirus is “clearly” a downside risk, but added that the current projections for U.S. gross domestic product growth this year “would be the most rapid return following a recession to ... the trend level of real GDP in 50 years.”

https://www.reuters.com/article/usa-fed-clarida/feds-clarida-backs-raising-interest-rates-in-2023-idUSW1N2OA026

https://www.marketwatch.com/investing/bond/tmubmusd10y

She saved Patriotism bros.

quiet notables bun @30

cakes, i gotta book. can you take over?

#483

>>79288 planefagg'n

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

>>79088, >>79108 pb

German AF GAF689 departed Key West NAS after an overnight wn

>>79302

cake gotz da dough

bounce

guud luck wit it

make it smooooooov on out

https://wtube.org/

Introducing wtube.org

No ads. No tracking. No censorship.

August 4, 1794 – Supreme Court Justice James Wilson certified that Whiskey Rebels were, "too powerful to be suppressed by the powers vested in the Marshal of that District." Washington called out the state militias.

https://twitter.com/USMarshalsHQ/status/1422935625230077952

Baker Hughes Company sold by General Electric Co.: $1.254B-August 3

from July 30, 2021

Baker Hughes Company Announces $2 Billion Share Repurchase Authorization

Baker Hughes Company (NYSE: BKR) ("Baker Hughes" or the "Company") announced today that its Board of Directors has authorized Baker Hughes Holdings LLC (“BHH LLC”) to repurchase up to $2 billion of its common units. The Company will use the proceeds from the sale of its BHH LLC common units to repurchase its Class A shares. Baker Hughes and BHH LLC are also authorized to enter into an agreement with GE whereby BHH LLC will repurchase its common units from GE on a pro rata basis and on the same terms as it repurchases common units from Baker Hughes. The proceeds distributed to Baker Hughes will be used to repurchase Class A shares on the open market or in privately negotiated transactions. The repurchases are not expected to materially change Baker Hughes and GE’s relative economic interests in BHH LLC or Baker Hughes’ Class A and Class B stockholders’ relative voting interest. Baker Hughes expects to fund the repurchase program from cash generated from operations. The exact number of shares to be repurchased by the Company is not guaranteed. The Company expects to make share repurchases from time to time subject to the Company’s capital plan, market conditions, and other factors, including legal and regulatory restrictions and required approvals. The repurchase program may be suspended or discontinued at any time and does not have a specified expiration date.

https://investors.bakerhughes.com/news-releases/news-release-details/baker-hughes-company-announces-2-billion-share-repurchase

Baker Hughes Company is an energy technology company. The Company operates through four business segments: Oilfield Services (OFS), Oilfield Equipment (OFE), Turbomachinery & Process Solutions (TPS), and Digital Solutions (DS). OFS designs and manufactures products and services for onshore and offshore oil and gas operations across the lifecycle of a well, including exploration, drilling, evaluation, completion, production, intervention and abandonment. OFE provides a portfolio of mission critical products and services utilized during drilling and over the life of a field. TPS provides equipment and related services for mechanical-drive, compression and power-generation applications across the oil and gas industry and energy industry. DS combines hardware technologies with enterprise-class software products and analytics to connect industrial assets, providing customers with the data, safety and security. The Company distributes products and services to oil and gas markets. Number of employees : 55 000 people.

https://www.marketscreener.com/quote/stock/BAKER-HUGHES-COMPANY-40311111/company/

https://finviz.com/insidertrading.ashx?oc=40545&tc=7&b=2

>>79307

dis you?

kekked when I read it

sumbudy predictin a "recession"

This is the actual results of the Elections. H/T Scooby Snacks.

@WeTheMedia @Forecast432Hz

https://t.me/Forecast432Hz/2708

>>79308

nope

Too many bans to try and werk through ober there.

ridiculous

Boeing 737 Max heads to China for key test to end flight ban

A Boeing Co. 737 Max jet is slated to leave for China within an hour to conduct a flight test for regulators, people familiar with the matter said, a step toward lifting the plane’s more than two-year grounding in the country following two fatal crashes. The 737-7 is scheduled to take off from Seattle’s Boeing Field at around 8 a.m. local time, bound for John Rodgers Field outside Honolulu, according to FlightRadar24, a flight-tracking site. Boeing didn’t immediately comment.

The Hawaii flight is the first leg of a trip across the Pacific, said the people, who asked not to be named because the matter is private. With the Max also barred from Russian airspace, the narrow-body plane will travel near the equator to China rather than take the shorter northern crossing that is typically flown by commercial aircraft. While the Max’s validation flight in China would be a milestone, the country’s regulators still could take months to wrap up their work before allowing the plane to resume commercial service. Boeing sent a delegation of around 35 pilots and engineers to the nation last month to meet with regulators and prepare for simulator and flight testing.

The stakes are enormous for Boeing, which hasn’t logged a major jet order from China in years as trade tensions simmered. The resumption of Max deliveries would bolster the company’s plans to speed production of its principal money maker as demand recovers from a global pandemic and a worldwide flying ban on the model.

About 175 nations have cleared the Max to resume service after Boeing redesigned a flight-control system linked to crashes in late 2018 and early 2019 that killed 346 people. Chief Executive Officer Dave Calhoun has been upbeat about prospects for the planemaker and the Max in China, after U.S. Deputy Secretary of State Wendy Sherman traveled to the country for diplomatic meetings. The Max will be cleared to fly in China and the rest of the globe by year-end, Calhoun said during the company’s earnings call last month. With the Winter Olympics looming and the effects of the COVID-19 pandemic hopefully receding, China’s airlines are clamoring to get the Max back in service, he said. Talks with CAAC, China’s air regulator, have been encouraging and constructive, Calhoun said.

https://www.bnnbloomberg.ca/boeing-737-max-heads-to-china-for-key-test-to-end-flight-ban-1.1636475

6 USAF C-130j Hercules heading ws from Bangor, ME

@ENERGY

SPECIAL DELIVERY: Exciting nuclear news out of @ORNL, which just got a shipment of advanced fuel rods that went through testing in a commercial reactor. Let the analysis begin! (via @GovNuclear) https://www.energy.gov/ne/articles/oak-ridge-national-laboratory-examine-westinghouse-accident-tolerant-fuel

https://twitter.com/ENERGY/status/1422942159385374728

>>79303

German AF GAF689 GLEX on final approach for Pensacola Int'l Airport, FL from Key West NAS depart and overnight

>>79315

did a fly by at Pensacola Int'l and nao heading west

>>79314

>>79292

sorry to hear

rough time for youth (always rough but more so now, too much pressure for young ones)

Blessings to you and your fam, friend.

bz

>>79321

(by 'youth' i don't mean just 16 year olds - dey stay young for a long time after dat, just don know it)

>>79322

still see'n baby steps

just not for walkin

>>79305

>wtube

hope it's as good as it sounds

i hate signing into anything anymore

dey gonna have to have people watching for illegal stuff tho

Donald J. Trump

August 4th, 2021

One of the biggest stories in the Lamestream Media yesterday was the very important Congressional race in Ohio and whether or not Trump-backed candidate, Mike Carey, would lose against a large and outstanding field of other candidates. The mainstream was chomping at the bit to report a loss for a Trump endorsed candidate—they couldn’t wait. In fact the Washington Post still hasn’t corrected their very old story. But lo and behold, instead of a loss, there was a landslide victory for Mike—a win far larger than even the most optimistic of polls. It was a great day for Ohio, but the story of this victory has been barely reported by the Fake News. If my endorsed candidate would have lost, it would have been nothing but front page. Such a double standard, but congratulations to Mike, he will never let Ohio down.

Donald J. Trump

August 4th, 2021

Three months ago, two wonderful Republican candidates in Texas defeated ALL Democrats, so the Congressional election last week was between two Republicans. My endorsed candidate won in the Primary, but the other outstanding candidate won the General Election because virtually 100% of Democrats, approximately 17% of the total vote, supported the candidate I did not endorse. I won because we ended up with a great Republican candidate—the Democrats never had a chance. Unfortunately, the Fake News never wrote that Democrats were in the race, obviously voting against me. It was a big Trump victory, a great Republican victory, and a great victory for American Patriot Congressman Jake Ellzey. Would really be nice if the Fake News would become real news

https://t.me/s/real_DonaldJTrump

>>79325

was hoping someone would trace it down

cloudfare, which can be cut on a dime?

always leary of copycats

everybody and thing too

kek

https://twitter.com/GeneralBrnovich/status/1422667204403732484

Our office recently fought a similar legal challenge to Arizona's election integrity measures and won in the #SCOTUS case 𝑩𝒓𝒏𝒐𝒗𝒊𝒄𝒉 𝒗. 𝑫𝑵𝑪.Read more about Arizona's #SCOTUS victory here:

Arizona Attorney General's Office

View this content on www.azag.gov

azag.gov

4:14 PM · Aug 3, 2021·Twitter Web App

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892316/

Autoimmun Rev. 2021 Apr; 20(4): 102792.

Published online 2021 Feb 19. doi: 10.1016/j.autrev.2021.102792

PMCID: PMC7892316

PMID: 33610751

The SARS-CoV-2 as an instrumental trigger of autoimmunity

Abstract

Autoimmunity may be generated by a variety of factors by creating a hyper-stimulated state of the immune system. It had been established long ago that viruses are a substantial component of environmental factors that contribute to the production of autoimmune antibodies, as well as autoimmune diseases. Epstein-Barr virus (EBV), cytomegalovirus (CMV) and human immunodeficiency virus (HIV) are viruses that withhold these autoimmune abilities. In a similar manner, SARS-CoV-2 may be counted to similar manifestations, as numerous records demonstrating the likelihood of COVID-19 patients to develop multiple types of autoantibodies and autoimmune diseases. In this review, we focused onthe association between COVID-19 and the immune systemconcerningthe tendency of patients to develop over 15 separate types of autoantibodies and above 10 distinct autoimmune diseases. Anadditional autoimmunity manifestationmay be one of the common initial symptoms in COVID-19 patients,anosmia, the complete loss of the ability to sense smell, and other olfactory alterations. We summarize current knowledge on principal mechanisms that may contribute to the development of autoimmunity in the disease:the ability of SARS-CoV-2 to hyper-stimulate the immune system, induce excessive neutrophil extracellular traps formation with neutrophil-associated cytokine responses and the molecular resemblance between self-components of the host and the virus. Additionally, we will examineCOVID-19 potential risk on the new-onsets of autoimmune diseases, such asantiphospholipid syndrome, Guillain-Barré syndrome, Kawasaki disease and numerous others. It is of great importance to recognize thoseautoimmune manifestations of COVID-19in order to properly cope with their outcomes in the ongoing pandemic and the long-term post-pandemic period. Lastly, an effective vaccine against SARS-CoV-2 may be the best solution in dealing with the ongoing pandemic. We will discuss the new messenger RNA vaccination strategy with an emphasis on autoimmunity implications.

Mexico Sues Smith & Wesson and Glock Over Smuggled Firearms

Mexico filed a lawsuit in a U.S. court Wednesday against Smith & Wesson Brands, Inc., Glock, Inc., Sturm, Ruger and Co. and other major gun manufacturers, alleging that negligence on their part contributes to arms trafficking south of the border.

The civil suit in a Massachusetts federal district court argues that the companies “wreak havoc in Mexican society, by persistently supplying a torrent of guns to the drug cartels”. “For decades the government and its citizens have been victimized by a deadly flood of military-style and other particularly lethal guns that flows from the U.S. across the border, into criminal hands in Mexico,” the country said in its lawsuit. “This flood is not a natural phenomenon or an inevitable consequence of the gun business or of U.S. gun laws. It is the foreseeable result of the defendants’ deliberate actions and business practices.”

The complaint names U.S.-based manufacturers “whose guns are most often recovered in Mexico”: Smith & Wesson, Glock and Sturm, Ruger and Co., Beretta U.S.A. Corp, Colt’s Manufacturing Company LLC and Century International Arms Inc. It also names Barrett, saying its .50-caliber sniper rifle “is a weapon of war prized by the drug cartels,” and Interstate Arms, a wholesaler. Smith & Wesson, Glock and Sturm, Ruger and Co. didn’t immediately reply to written requests for comment. In 2019, 17,000 Mexican citizens were murdered with guns manufactured in the U.S., compared to 14,000 citizens of the U.S. itself. This is despite Mexico having a smaller population and only one gun store, according to the suit. Mexico has long argued that gun smuggling from the U.S. needs to be addressed alongside the fight against drug trafficking, and President Andres Manuel Lopez Obrador’s government has raised the question with U.S. officials.

The country said it was suing “to put an end to the massive damage” that the gun makers cause by enabling the flow of weapons across the U.S.’s southern border, saying that almost all of the firearms recovered at crime scenes in Mexico come from the north.

https://www.bnnbloomberg.ca/mexico-sues-smith-wesson-and-glock-over-smuggled-firearms-1.1636543

Suing the wrong people...go after Hussein and Holder.

#483

>>79288, >>79303, >>79312, >>79313, >>79315, >>79316 Eyez to the skyz

>>79330 Mexico Sues Smith & Wesson and Glock Over Smuggled Firearms

>>79329 The SARS-CoV-2 as an instrumental trigger of autoimmunity

>>79328 Our office recently fought a similar legal challenge to Arizona's election integrity measures and won in the #SCOTUS case 𝑩𝒓𝒏𝒐𝒗𝒊𝒄𝒉 𝒗. 𝑫𝑵𝑪.

>>79326 45 talking congressional wins

>>79314, >>79317 @ORNL, which just got a shipment of advanced fuel rods that went through testing in a commercial reactor.

>>79312 Boeing 737 Max heads to China for key test to end flight ban

>>79309 This is the actual results of the Elections. H/T Scooby Snacks.

>>79307 Baker Hughes Company sold by General Electric Co.: $1.254B-August 3

>>79306 Rebels were, "too powerful to be suppressed by the powers vested in the Marshal of that District." Washington called out the state militias.

>>79305 Introducing wtube.org

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

#483

quick collect

feelin tired

lemme rest for a bit

back to collect and bake

Senior US diplomat Sherman speaks with Myanmar shadow government

Deputy Secretary of State Wendy Sherman spoke on Wednesday with a representative of Myanmar's government in exile, the first announced contact between a senior U.S. official and the rival administration to the generals who overthrew a democratically elected government.

The State Department said Sherman spoke with Zin Mar Aung, who has been appointed acting foreign minister in the shadow National Unity Government for Myanmar, also known as Burma. "They discussed ongoing efforts to return Burma to a path to democracy, including continued U.S. support for the pro-democracy movement," its statement said. "In addition, they discussed efforts to combat rising COVID-19 infections in Burma and to provide critical humanitarian assistance to the people of Burma."

Hours earlier, U.S. Secretary of State Antony Blinken met virtually with counterparts from the Association of Southeast Asian Nations and called on them to take joint action to urge the military to end violence, the State Department said. He also urged the group's foreign ministers to push for Myanmar to "release all those unjustly detained, and restore Burma's path to democracy," the earlier statement said.

https://asia.nikkei.com/Politics/International-relations/Senior-US-diplomat-Sherman-speaks-with-Myanmar-shadow-government

‘Unnecessary, misleading, catastrophic’: Senior European physicians co-author expert statement on COVID vaccine for children

July 30, 2021

Eminent European physicians and scientists this month co-authored an expert statement regarding Comirnaty–COVID-19 mRNA vaccine for children, outlining their expert opinions that “vaccination of adolescents for COVID-19 is unnecessary, claims demonstrating efficacy are misleading, and the safety profiles are catastrophic.”

Expert Statement:

https://americasfrontlinedoctors.org/files/declaration-of-bhakdi-hockertz-palmer-and-wodarg-unabridged/

It is authored by the former Chair of the Institute of Medical Microbiology and Hygiene, Johannes-Gutenberg University of Mainz Prof. emiretus Sucharit Bhakdi, M.D.; European registered toxicologist and immunologist and CEO of the TPI consult GmbH Prof. Dr. Stefan Hockertz; Facharzt für medizinische Mikrobiologie und Infektionsepidemiologie, Department of Chemistry, University of Waterloo Prof. Dr. Med. Michael Palmer; and Facharzt für innere Medizin-Lungen-und Bronchialkrankheiten, Facharzt für Hygiene und Umweltmedizin, Facharzt für öffentliches Gesundheitswesen Ltd. Med. Dir. i.R. Dr. Wolfgang Wodarg.

The document seeks to answer three questions:

• Is vaccination of adolescents against COVID-19 necessary?

• Is the Pfizer COVID-19 vaccine effective?

• Is the Pfizer COVID-19 vaccine safe?

....

VID CLIP: Dr. Bhakdi explains in the video clip that D-Dimer test shows the presence of blood clots "is a very comman event" with all the covid vaxxes. This is POTENTIALLY LETHAL....do NOT give the shot to children."If you give that jab to your child, you are committing a crime".

This article is CAPPED; expert statement is ATTACHED

https://www.lifesitenews.com/news/unnecessary-misleading-catastrophic-senior-european-physicians-co-author-expert-statement-on-covid-vaccine-for-children/

>>79334

Expert Statement:

https://americasfrontlinedoctors.org/files/declaration-of-bhakdi-hockertz-palmer-and-wodarg-unabridged/

Don't know the source, but this is worth thinking about.

Is the next step of 'green pass' (or any other vax certification) to STOP ACCESS TO POLLING STATIONS?

(Or to prohibit even voting by mail, for some kind of cooked-up reason?)

https://www.investmentwatchblog.com/italy-soon-unvaccinated-banned-from-voting/

from QR:

>>>/qresearch/14268618

ITALY : SOON Unvaccinated BANNED from Voting

August 4, 2021 by IWB

Green pass is now there. But Prime Minister Mario Draghi certainly does not stop at the first act, which is the obligation to show the green certificate to access restaurants and shows. The second act is already announced, with the pass that will become indispensable for boarding long-distance trains, airplanes and ferries. However, there is a third act, which is driving some jurists crazy: making certification mandatory to access the polling stations. A move that someone from Palazzo Chigi has been blurting out since yesterday afternoon, defining it as “the atomic bomb of Draghi”. A partial preview has already been provided by the secretary of the Democratic Party Enrico Letta, who wants only vaccinated candidates on the list. From the passive to the active electorate, however, the path is short.

Moar QUANT FAMILY (Amazing Polly)

IMPORTANT!!!!!

Direct connection to now just PCR Fraud Drosten, but also to his college Sandra Ciesek

https://www.bitchute.com/embed/yJyxhFswCnuZ/

ARCHIVE OFFLINE

>>79337

https://www.augsburger-allgemeine.de/panorama/Portraet-Sandra-Ciesek-ist-die-neue-Podcast-Partnerin-von-Christian-Drosten-id58068241.html

https://archive.is/mEsFm

Sandra Ciesek ist die neue Podcast-Partnerin von Christian Drosten

...

Aktuell leitet die in Goslar geborene Wissenschaftlerin das Institut für Medizinische Virologie am Universitätsklinikum in Frankfurt am Main und ist Professorin für Medizinische Virologie der Goethe-Universität. Bereits im Februar konnte die 42-Jährige mit ihrem Team nachweisen, dass auch symptomfreie Personen das Coronavirus in sich haben und somit übertragen können. Seitdem forscht sie vor allem zu Medikamenten gegen die Krankheit Covid-19 und an geeigneten Teststrategien. Im März erhielt sie von der Johanna-Quandt-Stiftung eine Fördersumme von 250.000 Euro für Coronaforschung – der Antrag wurde innerhalb von 24 Stunden bewilligt.

...

Sandra Ciesek is the new podcast partner of Christian Drosten

...

Currently, the Goslar-born scientist heads the Institute for Medical Virology at the University Hospital in Frankfurt am Main and is Professor of Medical Virology at Goethe University. Back in February, the 42-year-old and her team were able to prove that even symptom-free individuals carry the coronavirus and can thus transmit it. Since then, she has primarily been researching drugs against the Covid-19 disease and suitable testing strategies. In March, she received a grant of 250,000 euros from the Johanna Quandt Foundation for corona research - the application was approved within 24 hours.

...

I hope the Nazi-forced-labor-money was worth it.

>>79338

Back in February, the 42-year-old and her team were able to prove that even symptom-free individuals carry the coronavirus and can thus transmit it

And that seems to be fake science, see study from China.

Wow, these people were really fast. Drosten with his fraud PCR test and this bitch with her somehow finding out that there are infectious asymptomatic people.

Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

Russia is supplying more oil to the U.S. than any other foreign producer aside from Canada as American refiners scour the globe for gasoline-rich feedstocks to feed surging motor-fuel demand.

U.S. imports of crude and refined petroleum products from its former Cold War adversary surged 23% in May to 844,000 barrels a day from the prior month, government data showed. Mexico was edged out of the No. 2 spot as its shipments to its northern neighbor rose by less than 3%. Russia has become a favored source for U.S. fuel makers largely because it producers ample supplies of semi-refined oils such as Mazut 100, an ideal feedstock for American refineries accustomed to processing thick, sludgy crude from Venezuela and the Middle East. Cargoes from the former dried up due to sanctions, and OPEC-orchestrated output limits have crimped shipments from the latter, leaving an opening for Russian exporters.

The rise in Russian shipments is happening despite intensifying rancor between Washington and the Kremlin over a controversial pipeline that will haul Siberian gas to Germany. But in the absence of actual sanctions, U.S. companies are not bound by the diplomatic and geopolitical goals of the White House. Russian feedstock “seems to be functioning as a good substitute for Venezuelan oil, particularly in the high-demand summer season,” said Shirin Lakhani, a senior oil analyst at Rapidan Energy Group. Despite Russia’s ascendence, it’s no threat to Canada’s preeminence as the largest foreign crude supplier to the world’s biggest economy. In fact, Canada accounts for almost half of U.S. imports, delivering almost five times as much as Russia, the data showed.

Nevertheless, the importance of the U.S. market looms large in Moscow, where Federal Customs Service records show America is the single largest buyer of the nation’s heavy-oil products, the category that includes Mazut 100. U.S. buyers absorbed almost one-fifth of Russian heavy-oil exports during the first five months of the year. Most of the U.S.-bound Russian crude has docked along the West Coast to feed refineries like Phillips 66’s plant 100 miles (160 kilometers) north of Seattle and California refineries owned by Chevron Corp. and Valero Energy Corp., government data showed.

Refiners in Texas and Louisiana also have been buying Russian oil products; just last week, 1.5 million barrels from the Black and Baltic seas landed in the region. The influx was substantial enough to cut prices at the Houston Ship Channel by 3% earlier this week.

https://www.bnnbloomberg.ca/russia-captures-no-2-rank-among-foreign-oil-suppliers-to-u-s-1.1636599

>>79315, >>79316

German AF GAF689 GLEX with a few low altitude passes over El Paso Int'l and continues west.

>>79337

tx, anon.

i'll take notes on it, last Polly was great.

>>79337

https://www.stiftung-charite.de/en/

And here these Nazi-fucks are even part of the Foundation Charité.

Johanna Quandt (died AUG 3rd 2015)

Prof. Dr. E. Jürgen Zöllner - Chairman of the Board of Trustees

Prof. Dr. Detlev Ganten - Honorary Chairman of the Board of Trustees

Prof. Dr. Heyo Kroemer - Executive Board Chairman, Charitè - Universitätsmedizin Berlin since September 1st 2019.

Astrid Lurati - Hospital Director, Charité - Universitätsmedizin Berlin

Prof. Dr. Brigitte Oetker - Editor

Prof. Dr. Axel R. Pries - Dean of the Medical Faculty, Charité Universitätsmedizin Berlin

Stefan Quandt- Entrepreneur, Vice Chairman of the Board of Trustees

Prof. Dr. Jens Schneider-Mergener - University Professor, Charité - Universitätsmedizin Berlin and Founder of Jerini AG

>>79342

We need to archive all of this asap.

And the other board members have to get looked at as well.

Kek! Just saw one of you at a little store called Celtic in a tiny little town. Hey a fren!

>>79337

It gets even better:

Jasmin QUANDT - Scientist at BioNTech

https://de.linkedin.com/in/jasmin-quandt-539625182

https://archive.is/ivexP

Jasmin Quandt

Scientist bei BioNTech SE

Mainz, Rhineland-Palatinate, Germany

About

I am a Biochemist/Biologist by training with 11 years of experience in Tumor Immunology Research. I have a particularly strong interest in investigating topics in immune oncology that could pave the way for clinical applications and new drug development. After my PhD studies at the German Cancer Research Center in the field of Translational Tumor Immunology, I was seeking experiences abroad as a Postdoctoral Researcher in the United States. Recently I ventured into the exciting world of cooperate (cancer) vaccine development.

Through my work in this exciting, interdisciplinary research field I was able to gain expertise in immune response readout technologies, tumor models, immunological assessment of patient material, and molecular techniques. Collaborations with clinicians and other life science disciplines as well as sharing my knowledge through teaching and instructing others I happily welcome on my journey as I can only learn from them myself.

I am always curious exploring new avenues of how to contribute to impactful biomedical research and applications.

Experience

BioNTech SE

Scientist

Company Name

BioNTech SE ·Full-time

Dates Employed Apr 2020 – Present

Employment Duration ·1 yr 5 mos

Location Mainz, Rheinland-Pfalz, Deutschland

Postdoctoral Research Scholar

Company Name

University of Chicago ·Full-time

Dates Employed May 2015 – Apr 2020

Employment Duration ·5 yrs

Location Chicago, IL, USA

Investigating the epigenetic re-programming of regulatory T cells (Tregs) through Wnt-signaling activation in inflammatory bowel disease and colorectal cancer

DKFZ German Cancer Research Center

Total Duration 5 yrs 6 mos

Title Wissenschaftliche Mitarbeiterin

Full-time

Dates Employed Nov 2014 – Apr 2015

Employment Duration ·6 mos

Location Heidelberg, Baden-Württemberg, Deutschland

Title Forschende Doktorandin/PhD Student

Full-time

Dates Employed Nov 2009 – Oct 2014

Employment Duration ·5 yrs

Location Heidelberg

Development of a pre-clinical long-peptide vaccine against driver gene mutations of GI tumors in p53 and Kras and establishment of a MHC-humanized mouse tumor model

Studentische Hilfskraft

Company Name

Universität Ulm ·Part-time

Dates Employed Aug 2006 – Sep 2009

Employment Duration ·3 yrs 2 mos

Location Ulm und Umgebung, Deutschland

Unraveling the control of octamer-dependent transcription by NFAT/NF-κB signaling in B & T cells

Education

Ruprecht-Karls-Universität Heidelberg

Ruprecht-Karls-Universität Heidelberg

Degree Name Doktor (Dr. rer. nat),

Field Of Study Biology, Tumor Immunology

Dates attended or expected graduation 2009 – 2014

Universität Ulm

Universität Ulm

Degree Name Master of Science - MS,

Field Of Study Biochemistry

Dates attended or expected graduation 2007 – 2009

Activities and Societies: Uni-Ballett Ulm

Universität Ulm

Universität Ulm

Degree Name Bachelor of Science - BS,

Field Of Study Biochemistry

Dates attended or expected graduation 2004 – 2007

Activities and Societies: Uni-Ballett Ulm

>>79346

Accomplishments

Jasmin has 10 publications 10

Publications

Wnt/β-catenin activation epigenetically reprograms Regulatory T cells in IBD and progression to dysplasia •BNT162b2induces SARS-CoV-2-neutralising antibodies and T cells in humans •Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine •TCF-1 and HEB cooperate to establish the epigenetic and transcription profiles of CD4+CD8+ thymocytes. •Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses •β-catenin signaling mediates pathogenic pro-inflammatory conversion of Foxp3+ Treg cells early during colon cancer development •NF-κB-dependent signals control BOB.1/OBF.1 and Oct2 transcriptional activity in B cells •A vaccine targeting mutant IDH1 induces antitumour immunity •T cell responses against mutations in oncoproteins/tumor suppressor proteins and their induction by vaccination with long peptides •Octamer-dependent transcription in T cells is mediated by NFAT and NF-κB

Jasmin has 5 courses 5

Courses

Basics in Economy (Grundlagen der Betriebswirtschaftslehre) •Development, permission, and controlling of drugs •Effective Writing for Life Science Research •FELASA B •Patentrecht

Jasmin has 3 languages 3

Languages

Deutsch •Englisch •Französisch

Jasmin has 2 honors 2

Honors & Awards

AAI (The American Association of Immunologists) Careers in Immunology Fellowship •CIMT 2011 Poster Award

Anyone got a linkedin account and can check her connections?

>>79341

German AF GAF698 GLEX on ground at Goodyear Airport Phoenix, AZ

>>79337

>>79337

Amazing Polly: ENTRUST cont - "I just think they want slaves again!"

Quandt Fam & ENTRUST, con't. See >>78676 pb

Depopulation, slave labor, eugenics - goals for Nazis and for fams like Quandts

Now that they have the tech, they're trying to implement it.

Today:

a few more threads.

1. Reiner Fuellmich is trying to sue all these people like Christian Drosden. Was his education paid for by Joanna Quandt? Supposedly part of the testimony in this case. ALSO: Did she place him in his current position at the Charite Hospital that has become his platform? Drosden legitimized the PCR test.

This is still up in the air but WORTH A DIG.

1. Fully substantiated: '''Drosden's partner Sandra Ciesek was given 250,000 Euros for "corona research."' She promotes LOCKDOWN.

1. Charite Hospital history: They experimented on children in the past - with drugs killed them. Horror show.

1. Drosden was at a conference where he spoke on the same time as Event 201 on infectious disease emergence. (that's what Peter Daszak focuses on too).

1. Jennifer Quandt works at the Wellcome Trust - related to fam? (also spoke at same conference as Drosden in Oct 2019)

1. from a commenter:

a. there is a Jasmine Quandt at BioNTech SE; also worked at German Cancer Research Ctr. Related?

b. Rob Quandt works at WILDTYPE, Merck related. Astrozenica-related. from Salzberg, Germany.

related???

1. Suzanne Klatten well-positioned to participate in Great Reset. Involved in business "incubator". Hi tech startups. Leading center in Europe. They mentor young entrepreneurs from all over the world. Into Smart Cities (there's more on Smart Cities).

8. "Educating the Next Wave of Entrepreneurs" - 2009. From World Economic Forum. WEC plus Nazis.

1. Bosch Company involved. Another old German company. They also used 20,000 slave laborers during WW2. No penalties after the war. Robert Bosch start it, also uncle of Carl (sp?) Bosch -FOUNDER OF IG FARBEN. Carl Bosch also started the Green Revolution, "feeding the world", spraying crops. Was it to save the world or poison it? Head of Kaiser Wilhelm Society, where they experimented on TWINS. The company Bosch is still going today - excited about Klatten's enterpreneurial efforts. Into "sustainable development." THEY'RE LYING - THEY ARE PSYCHOTIC MANIACS.

1. Wintershall - another German company that used slave labor. owned now by ENTRUST - making cv 19 VAX PASSPORTS.

PAGE 1

>>79350

IMAGES con't.

note the MP4 - Polly talking about what it all means.

>>79343

Sponsors and Partners

Scottish Government

Riaghaltas na h-Alba

gov.scot

#SCOTLANDISNOW

Sponsors Berlin Institute of Health (BIH) @Charité

High-Tech Gründerfonds

>>79348

sorry, no acct here

Wonder how common a name Quandt is in Germany?

>>79343

https://www.stiftung-charite.de/en/conferences/charite-entrepreneurship-summit/speakers

Speakers 2021

GAYLENE ANDERSON

Director, Global Transactions and Contracts Management, Boehringer Ingelheim Pharmaceuticals, Inc., Connecticut USA

As Boehringer Ingelheim’s Director, Global Transactions and Contracts Management, Gaylene is responsible for negotiating license/collaboration deals, research agreements, and managing strategic alliance programs. Prior to joining BI, Gaylene served as the Director, Cleveland Clinic/ University of Notre Dame Global Alliance Commercialization Program – managing all life science IP, negotiating license deals and research opportunities, and spinning out startup companies.

Throughout her career, Gaylene has had a strong focus on economic development and entrepreneurship activities. As a result, she has created over a dozen startup companies, developed relationships with investor groups around the U.S., and helped grow research collaboration opportunities for university programs. Prior to the Cleveland Clinic, she worked for the University of Idaho and the University of Hawaii, as a Senior Licensing Associate.

Gaylene has won several leadership awards for her work with faculty and students, particularly with respect to her entrepreneurial accomplishments (including her own company, Waterproof Kids®).

CHRISTOPHER BAUM

Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin, Germany

Professor Christopher Baum was born in 1962 in Marburg. He studied philosophy for two semesters in Mainz, and medicine in Essen, Freiburg and Hamburg. He obtained his doctorate in 1991, and qualified as a professor in the field of molecular medicine in 1999 at the University of Hamburg. In 2000, he joined the Hannover Medical School (MHH) as a professor for stem cell biology, and was also an associate professor of pediatrics at the Cincinnati Children’s Hospital in the United States from 2002. In Hanover, he led the Institute of Experimental Hematology from 2006 and served as both the Ombudsperson for Good Scientific Practice and the Dean of Research. He was elected President of the MHH in 2013. At the beginning of 2019, Baum moved to the University of Lübeck as its first full-time Vice President for Medicine and a member of the Board of Directors of UKSH – Germany’s second largest university hospital after Charité. Since October 2020 Christopher Baum has been Chief Executive Officer of th Berlin Institute of Health (BIH). With the integration of the BIH into the Charité – Universitätsmedizin Berlin, Baum has become Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin.

>>79354

LINA BEHRENS

Managing Director at Flying Health GmbH, Berlin, Germany

Lina Behrens is a Managing Director at Flying Health, the leading ecosystem for Next Generation Healthcare. She is also Vice President of the German Startup Association and a Member of the Advisory Board „Junge Digitale Wirtschaft“ (Young Digital Economy) of the German Federal Ministry of Economics and Energy. Previously, Lina worked at the Boston Consulting Group (BCG) and at Polymath Ventures, one of the largest company builders in Latin America. Lina holds an MPA from the London School of Economics and a BA in Economics and in International Affairs from the University of St. Gallen.

JOHN S. BROWNSTEIN

Chief Innovation Officer at Boston Children’ Hospital, Boston, Massachusetts, USA

Professor of Biomedical Informatics at Harvard Medical School and is the Chief Innovation Officer of Boston Children’s Hospital. He also directs the Computational Epidemiology Lab and the Innovation and Digital Health Accelerator both at Boston Children’s. He was trained as an epidemiologist at Yale University. Overall, his work aims to have translation impact on the surveillance, control and prevention of disease. He has been at the forefront of the development and application of data mining and citizen science to public health. His efforts are in use by millions each year including the CDC, WHO, DHS, DOD, HHS, and EU, and has been recognized by the National Library of Congress and the Smithsonian. In addition to research achievements, this translational impact comes from playing an advisory role to numerous agencies on real-time public health surveillance including HHS, DHS, CDC, IOM, WHO and the White House. He was awarded the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the United States government to outstanding scientists and the Lagrange Prize for international achievements in complexity sciences. Dr. Brownstein is co-founder of digital health companies Epidemico and Circulation and an ABC Medical News Contributor. He has authored over 250 peer-reviewed articles on epidemiology and public health. This work has been reported on widely including pieces in the New England Journal of Medicine, Science, Nature, New York Times, The Wall Street Journal, CNN, National Public Radio and the BBC.

>>79355

ARTHUR CAPLAN

Drs. William F and Virginia Connolly Mitty Chair Director, Division of Medical Ethics, NYU Grossman School of Medicine, NY USA

Currently the Drs. William F and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City.

Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He received his PhD from Columbia University.

Dr. Caplan is the author or editor of thirty-five books and over 800 papers in peer reviewed journals. His most recent books are Vaccination Ethics and Policy, (MIT Press, 2017 with Jason Schwartz) and, Getting to Good: Research Integrity in Biomedicine Springer, 2018 with Barbara Redman).

He has served on a number of national and international committees including as the chair of the National Cancer Institute Biobanking Ethics Working Group, chair of the Advisory Committee to the United Nations on Human Cloning; chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability. He has also served on the Presidential Advisory Committee on Gulf War Illnesses, the special advisory committee to the International Olympic Committee on genetics and gene therapy, the Special Advisory Panel to the National Institutes of Mental Health on Human Experimentation on Vulnerable Subjects, the Wellcome Trust Advisory Panel on Research in Humanitarian Crises, and the co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts. He is the co-founder and a member of the ge2p2 global foundation.

Caplan has served since 2015 as the chairperson of the Compassionate Use Advisory Committee (CompAC), an independent group of internationally recognized medical experts, bioethicists and patient representatives which advises Johnson & Johnson’s Janssen Pharmaceuticals about requests for compassionate use of some of its investigational medicines.

Dr. Caplan is a regular commentator on bioethics and health care issues for WebMD/Medscape, WGBH radio in Boston, WOR radio in New York City and CNN. He appears frequently as a guest and commentator on various other national and international media outlets.

Dr. Caplan is the recipient of many awards and honors including the McGovern Medal of the American Medical Writers Association and the Franklin Award from the City of Philadelphia. He was a USA Today 2001 “Person of the Year and was described as one of the ten most influential people in science by Discover magazine in 2008. He has also been honored as one of the fifty most influential people in American health care by Modern Health Care magazine, one of the ten most influential people in America in biotechnology by the National Journal, one of the ten most influential people in the ethics of biotechnology by the editors of Nature Biotechnology, and one of the 100 most influential people in biotechnology by Scientific American magazine.

During the Covid-19 pandemic, he co-directs an advisory group on sports and recreation for the US Conference of Mayors, created a working group on coronavirus vaccine challenge studies, developed an ethical framework for distributing drugs and vaccines for J&J, helped develop rationing policies for NYU LMC and many other health systems, is a member of the WHO advisory committee on Covid, ethics and experimental drugs/vaccines, helped set policy for WIRB/WCG for research studies He was an advisor to Moderna. And serves on the NCAA Sports and Covid committee.

He received the Patricia Price Browne Prize in Biomedical Ethics for 2011. In 2014 he was selected to receive the Public Service Award from the National Science Foundation/National Science Board, which honors individuals and groups that have made substantial contributions to increasing public understanding of science and engineering in the United States. In 2016 the National Organization for Rare Disorders (NORD) honored him with their Rare Impact Award and hFood and Drug Law Institute’s Distinguished Service Leadership Award. In 2019 he was honored by the Food and Drug Administration’s, Reagan/Udall Foundation with its Innovation Award.

He holds seven honorary degrees from colleges and medical schools.

>>79356

HORST DOMDEY

Managing Director at BioM Biotech Cluster Development GmbH, Planegg, Germany

In his scientific career, Horst Domdey worked at various German, Swiss and US institutes such as the Max Planck Institute of Biochemistry, the Swiss Institute of Cancer Research, the University of California at San Diego, the California Institute of Technology and the Munich Gene Center, where he was appointed as Professor of Biochemistry in 1994. In 1996 he successfully led the Munich Biotech Initiative into the German BioRegio Competition. Since 1997 he is the Managing Director of BioM, the development and management organization of the Munich Biotech Cluster, since 2006 he also directs the Bavarian Biotechnology Network. Among others he is a member of the boards of the Peter and Traudl Engelhorn Foundation and the Foundation for Stem Cell Research and Applied Regenerative Medicine.

GEORG N. DUDA

Founding director of Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies (BCRT) Charité - Universitätsmedizin Berlin, Germany

Georg is the founding director of the Julius Wolff Institute at the Charité, Humboldt University and Free University of Berlin. The Julius Wolff Institute brings together researchers from engineering, mathematics, biology, biochemistry and clinical scientists in order to develop new therapeutic strategies for regeneration of injured or degenerated joint, bones and muscles. Conceptually, Georg’s research aims at understanding endogenous cascades of tissue formation, cytokine signaling and cellular self-organization especially in bone. This understanding is transferred to enable regeneration in clinically challenging healing scenarios of tissues normally capable of regeneration (bone) and those with intrinsic impaired regenerative capacity. Mechanical straining and adaptation due to mechanical cues plays a central role in all these tissues. The aim of Georg’s work is to understand the mechano-biological cues of regeneration and adaptation and how they can be employed to enable healing even in tissues with impaired regenerative capacity such as muscle, cartilage or tendon. All approaches are motivated by clinical challenges, employ basic research principles and aim at being translated into daily clinical routine. Examples of translation include innovative concepts for joint replacement procedures, angle stable fixation of implants or cell therapies for muscle regeneration.

Given his broad interest, core to all his activities is the close collaboration with clinical partners, specifically the scientific education of clinical scientists as core members of his team of research.

Georg Duda is Professor of Biomechanics and Musculoskeletal Regeneration at the Charité – Humboldt University of Berlin and Free University of Berlin and an Associated Faculty Member at the Wyss Institute for Biologically Inspired Engineering at Harvard University. He received his Master’s degree in precision engineering from the Technical University of Berlin, Germany, in 1991 and his Ph.D. degree in Mechanical Engineering from the Technical University of Hamburg-Harburg in 1996. He has been recipient of over a dozen awards for inventions, start-up engagements and PhD student mentoring.

>>79357

DAME ANNA DOMINICZAK

Regius Professor of Medicine University of Glasgow, Scotland

Professor Dame Anna Dominiczak is Regius Professor of Medicine at the University of Glasgow; Honorary Consultant Physician and Endocrinologist at NHS Greater Glasgow and Clyde; and Health Innovation Champion for the Medical Research Council. In 2016, she was awarded a DBE for services to cardiovascular and medical science.

Professor Dominiczak is currently seconded to the Department of Health and Social Care in the UK Government as Director of Laboratories, NHS Test & Trace. In March 2020, she successfully led the establishment of the Lighthouse Laboratory in Glasgow (LLiG), leading to her current role where she continues to expand the Lighthouse laboratory network. She is accountable for the UK labs testing capability across a coordinated network of 13 labs. As the network continues to evolve, and very high throughput labs are brought online, Professor Dominiczak’s focus remains on delivering a triple helix partnership between academia, the NHS and industry to transform the long-term testing capability of the UK for COVID and beyond.

Recognised as a world-leading cardiovascular scientist and clinical academic, her major research interests are in hypertension, cardiovascular genomics and precision medicine, where she not only publishes extensively in top peer-reviewed journals (over 500 publications), but also excels in large scale research funding for programmes and infrastructure (with a total value in excess of £100M over the last eight years).

>>79358

MARC FILERMAN

Managing Partner at German Accelerator Life Sciences, Cambridge, Massachusetts, USA

Marc Filerman is a healthtech entrepreneur and intrapreneur with expertise in market development, commercialization, and innovation acceleration. He has broad experience leading marketing, sales, and business development for large companies and startups. Marc co-founded a molecular imaging startup, was Chief Commercial Officer at an NIH-funded hometech venture, and was an Accelerator Executive with the CIMIT accelerator at Massachusetts General Hospital. Prior to his entrepreneurial endeavors Marc held corporate leadership positions in multiple large healthtech companies, including VP of Global Marketing at iCAD, Group Director of Marketing at Smith & Nephew, and Director of Global Marketing and Strategy at Hill-Rom. Marc holds BS and MS degrees from MIT in Mechanical Engineering, did his graduate work at the MIT AI Lab, and started his career as an engineer designing ultrasound imaging equipment for echocardiography.

MEREDITH FISHER

Partner at Mass General Brigham Ventures, Cambridge, Massachusetts, USA

Dr. Meredith Fisher is a Partner with the Innovation Fund focusing on early stage investments and company creation. Previously, she was in the private office at Bracebridge Capital serving as Director of Private Investments where she led investments in early stage life science companies. Prior to that role she led business development for Ginkgo BioWorks- an MIT spin out- and was Senior Director of Technology and Business Development at PureTech Ventures. She spent several years working as a scientist in drug discovery and assay development for Idenix Pharmaceuticals and Anadys Pharmaceuticals. Meredith serves as a board member on Nocion, ClarisBio, ZielBio and Mediar Therapeutics where she is co-founding CEO. She is an Observer on Amolyt Pharma and Scorpion Therapeutics. Meredith received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management and her PhD from Harvard University.

>>79359

OLIVER HAYDEN

Heinz-Nixdorf-Chair of Biomedical Electronics, Director TranslaTUM at TU München, Germany

Employment

03/2019

Director of the Center for Translational Cancer Research (TranslaTUM), Campus University Hospital Klinikum rechts der Isar, TUM, Germany

06/2017

Heinz-Nixdorf-Chair of Biomedical Electronics, Department of Electrical and Computer Engineering, TU Munich, Germany

11/2016 - 05/2017

Head of In-Vitro Diagnostics & Bioscience Germany, Siemens Healthcare GmbH, Technology Center, Erlangen, Germany

05/2015 - 10/2016

Senior Key Expert Scientist at Siemens Healthcare GmbH, Technology Center, Erlangen, Germany

05/2007 - 04/2015

Program Manager at Siemens AG, Corp. Technology, Erlangen, Germany

08/2005 - 04/2007

Visiting Scientist at IBM Research GmbH, Zürich Research Laboratory, Rüschlikon, Switzerland

01/2000 - 07/2005

Assistant Professor at the Institute of Analytical Chemistry, University of Vienna, Austria

Awards

2017 - European Inventor Award (category industry for hematology analysis of Plasmodium infections, Patent EP 2 635 695 B1, 2011)

2016 - Innovation Award of AMA (Association for Sensors & Measurement)

2013 - Siemens NTF Award for Medical Imaging IP portfolio 2006 EUREKA Lillehammer Award (E! 2497 Euroenviron BIOMAC) 2002 Young Investigator Award of the Austrian Chemical Society

2000/2001 - Award winner of “Best of Biotech” for start-up competition “Polymimetics”

Research Expertise & Interests

• Current research @ TUM: in vitro & in vivo diagnostics

• Industrial research: 12yrs in the semiconductor and healthcare industry on post-CMOS, medical imaging, in vitro diagnostics, and bioscience topics

• Academic training: 5yrs on piezoacoustic sensing and semiconducting nanowire sensing

>>79360

ANH HOANG

Founder and Chief Science Officer at Sofregen Medical, Framingham, Massachusetts, USA

Dr. Anh Hoang, is the founder of Sofregen Medical, a medical device company that re-invents silk protein for tissue engineering. At Sofregen, Anh currently operates as the chief science officer and serves on the board of directors. Under her leadership, Sofregen obtained the first FDA clearance for the use of re-constituted silk protein for a medical application.

Outside of Sofregen, Anh is a faculty at Massachusetts Institute of Technology’s Catalyst LinQ program . She serves on the Medtech Advisory Group at the Massachusetts Biotechnology Council and on the Steering Committee of MassMedic Ignite Program. She was a recipient of the 2018 Medtech Boston 40 under 40 Healthcare Innovators.

Anh completed her doctorate degree (Ph.D) in material science engineering from Vanderbilt University and her postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital as an Executive Committee on Research fellow. Anh is a proud graduate of Mount Holyoke College where she earned her bachelor’s degree in biochemistry.

>>79361

ANH HOANG

Founder and Chief Science Officer at Sofregen Medical, Framingham, Massachusetts, USA

Dr. Anh Hoang, is the founder of Sofregen Medical, a medical device company that re-invents silk protein for tissue engineering. At Sofregen, Anh currently operates as the chief science officer and serves on the board of directors. Under her leadership, Sofregen obtained the first FDA clearance for the use of re-constituted silk protein for a medical application.

Outside of Sofregen, Anh is a faculty at Massachusetts Institute of Technology’s Catalyst LinQ program . She serves on the Medtech Advisory Group at the Massachusetts Biotechnology Council and on the Steering Committee of MassMedic Ignite Program. She was a recipient of the 2018 Medtech Boston 40 under 40 Healthcare Innovators.

Anh completed her doctorate degree (Ph.D) in material science engineering from Vanderbilt University and her postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital as an Executive Committee on Research fellow. Anh is a proud graduate of Mount Holyoke College where she earned her bachelor’s degree in biochemistry.

LUCIO IANNONE

Senior Director Venture Investments Leaps by Bayer, Cambridge, MA, USA

Lucio Iannone is an investor at Leaps by Bayer, the investment arm of the global life sciences company Bayer. Lucio is responsible for developing investment cases and deal execution. He is also involved in the sourcing, screening, and mentoring of companies with game-changing science. As an investor, Lucio is serving as board member for Pyxis Oncology, Khloris Biosciences, Vesigen Therapeutics , Immunitas Therapeutics, eGenesis, Azitra, Kojin Therapeutics and Axxam. Before joining Leaps by Bayer, he had several senior roles in biotechnology companies and venture capital firms. He has experience with molecular biology, cell & gene therapy technologies and their application in oncology and other therapeutic fields. Lucio obtained his Ph.D. in Medicine at the Imperial College of London and Master in Molecular Biology from Cambridge University.

>>79362

REGINA HODITS

Managing Partner at Wellington Partners Life Sciences (WPLS), Munich, Germany

Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma Therapeutics, ONWARD, Sidekick, SNIPR Biome and STipe Therapeutics. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), represented Wellington Partners of the Board of Themis (acquired by MSD), and served as the Spokesperson for the Board of the German PE and VC Association (BVK). Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals in Life Sciences.

Before joining WPLS, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics (NASDAQ: BCYC), F-star (NASDAQ,: FSTX) and Jenavalve, and served on the Boards of U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), and Novamed (acquired by SciClone NASDAQ SCLN). Before, Regina worked for Apax Partners and McKinsey.

Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry, and was as post-doctoral researcher at the MRC, Cambridge UK.

KATALIN KARIKÓ

Senior Vice President RNA Protein Replacement Therapies at BioNTech, Mainz, Germany

Katalin Karikó is Senior Vice President at BioNTech RNA Pharmaceuticals from 2013. She is also Adjunct Associate Professor at the Perelman School of Medicine, University of Pennsylvania, where she worked for 24 years. She received her PhD in biochemistry from University of Szeged, Hungary, in 1982. For four decades, her research has been focusing on RNA-mediated mechanisms with the ultimate goal of developing in vitro-transcribed mRNA for protein therapy. She investigated RNA-mediated immune activation and co-discovered that nucleoside modifications suppress immunogenicity of RNA. This groundbreaking work unlocked the opportunity for the therapeutic use of mRNA. Her patents, co-invented on nucleoside-modified uridines of mRNA, was the foundation for the FDA-approved anti-SARS-CoV-2 mRNA vaccines developed by BioNTech/Pfizer and Moderna/NIAID that are crucial to ending the global pandemic.

SEKAR KATHIRESAN

CEO at Verve Therapeutics, Cambridge, USA

Sekar Kathiresan is co-founder and chief executive officer of Verve Therapeutics and serves on the company’s board of directors. He is a preventive cardiologist who has made groundbreaking discoveries of cardioprotective genetic mutations, which confer resistance to cardiovascular disease. Prior to joining Verve, he served as director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine and was the Ofer and Shelly Nemirovsky MGH Research Scholar. He also served as director of the Cardiovascular Disease Initiative at the Broad Institute and was professor of medicine at Harvard Medical School. His research laboratory focused on understanding the inherited basis for blood lipids and myocardial infarction and using these insights to improve preventive cardiac care. Among his scientific contributions, he has helped highlight new biological mechanisms underlying heart attack, discovered mutations that protect against heart attack risk, and developed a genetic test for personalized heart attack prevention. He was honored with a Distinguished Scientist Award from the American Heart Association in 2017 and the 2018 Curt Stern Award from the American Society of Human Genetics. In tandem with his research, his clinical focus was the primary prevention of myocardial infarction in individuals with a family history of heart attack. He graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. He completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.

>>79363

HEYO K. KROEMER

Chief Executive Officer at Charité – Universitätsmedizin Berlin, Germany

A pharmacologist by trade, Prof. Kroemer was born in 1960 in the Eastern Friesland area of Germany, Prof. Kroemer trained as a pharmacologist. From 2000 to 2012, he was Dean of the Medical School at the institution now known as the University of Greifswald. In 2011, he was appointed Scientific Director of Universitätsmedizin Greifswald. After joining the Board in 2007, Prof. Kroemer became President of the German Association of Medical Faculties (MFT) in 2012, a position he held until 2019. During this time, he was both Dean and Chairman of the Board of the University of Göttingen Medical Center. Prof. Kroemer was appointed Charité’s Chief Executive Officer on 1 September 2019.

MADELEINE KÜNZ

Senior Consultant – Market Access & Regulatory Strategie at Kalms Consulting, Berlin

Dr. Madeleine Künz academic background is reseach in Molecular Life Sciences, Structure Biology and Chemistry. Before joining Kalms Consulting, she worked for over 10 years in international research facilities and the pharmaceutical industry. Her research mainly concentrated on rational drug development in international interdisciplinary working groups combining approaches from structural biology, biophysics and chemistry. Her understanding of medical technologies is supported by her additional education and work experience as a paramedic for 7 years as well as advanced education in health technology assessment (HTA). Especially diagnostic but also therapeutic procedures including digital health products are part of her expertise. Furthermore, differentiation as well as compatibility assessments allow her to draw an accurate picture of innovation´s value. Her work in Kalms Consulting is centered around the assessment of innovative technologies and translation of these into options for the regulatory and market access strategy.

JASON LEITCH

National Clinical Director at Scottish Government, Scottland

Jason has worked for the Scottish Government since 2007 and in January 2015 was appointed as The National Clinical Director in the Health and Social Care Directorate. He is a Scottish Government Director and a member of the Health and Social Care Management Board. He is one of the senior team responsible for the NHS in Scotland.

He is an Honorary Professor at the University of Dundee.

Jason was the 2011 UK Clinician of the Year.

He is a Senior Fellow at the Institute for Healthcare Improvement (IHI). He was a 2005-06 Quality Improvement Fellow at IHI, in Boston, sponsored by the Health Foundation.

>>79364

SARAH LEVY-SCHREIER

CTO at Sight Diagnostics

Sarah joined Sight to build and lead its technology dream-team. She is responsible for all of Sight's R&D as well as its medical-regulation activities. Top of her class at the elite Talpiot program, Sarah gained her technology leadership experience during a brilliant military career, where she commanded elite cyber security and intelligence special technology units.

Sarah holds as M.Sc. in Condensed Matter Physics from the Weizmann Instituter of Science, and a B.Sc in Physics & Mathematics (magna cum laude) from the Hebrew University of Jerusalem.

NEEMA MAYHUGH

Managing partner and founder WAVE STRATEGY, Cleveland, Ohio, USA

MANAGING PARTNER

Neema Mayhugh is a healthcare innovation expert who helps large academic medical centers and biotechnology incubators bridge the gap between research and product delivery. Neema designs and executes a comprehensive strategy to take technology from bench to bedside -- engaging partners, securing capital, and delivering desired outcomes, always with an eye toward ensuring the highest quality patient care and enhancing the patient experience.

Built on a solid foundation of clinical innovation, Neema’s expertise stems from strong basic research training and early positions in healthcare management consulting and with Pfizer, Inc. Her specialization then grew rapidly when she joined the industry-leading Cleveland Clinic, where her roles and responsibilities expanded to include:

~ Start-up formation

~ Licensing

~ Intellectual property portfolio prioritization

~ Clinical trial management and execution

~ Sponsored research program negotiation

~ Management of commercialization projects

~ Strategic portfolio oversight

As Chief Operating Officer of Mobile Hyperbaric Centers, Neema expanded her expertise base again, overseeing operations for seven hospital centers and all corporate functions including insurance authorization, billing, documentation, compliance, human resources and center safety and maintenance.

Neema holds a Doctoral degree in Pharmacology & Toxicology from Dartmouth College and a Bachelors of Science in Human Physiology from Boston University.

>>79365

NICHOLAS MILLS

Chair of Cardiology & Consultant Cardiologist at University of Edinburgh

Current post: British Heart Foundation (BHF) Butler Senior Clinical Research Fellow (personal fellowship, 2016-2021) and Personal Chair of Cardiology, BHF/University Centre for Cardiovascular Science, University of Edinburgh. Consultant Interventional Cardiologist, Royal Infirmary of Edinburgh.

Previous appointments:

2013 - 2015 Reader in Cardiology, University of Edinburgh

2011 - 2016 BHF Intermediate Clinical Research Fellow, University of Edinburgh

2011 - 2013 Senior Lecturer in Cardiology, University of Edinburgh

2007 - 2011 Clinical Lecturer in Cardiology, University of Edinburgh

2005 - 2011 Specialist Registrar in Cardiology, Royal Infirmary of Edinburgh

2005 - 2007 Michael Davies/British Cardiac Society Research Fellow, University of Edinburgh

2003 - 2005 British Heart Foundation Research Fellow, Edinburgh University, Edinburgh

2001 - 2003 South East of Scotland Senior House Officer Rotational Training Scheme in Medicine

2000 - 2001 Pre-registration House Officer Posts, Western General Hospital, Edinburgh

Education:

BSc (First Class Honours) Edinburgh University 1998

MB ChB Edinburgh University 2000

MRCP Royal College of Physicians 2003

PhD Edinburgh University 2009

Selected Grants:

British Heart Foundation UK Cardiovascular Regeneration Medicine centre Award Renewal (RM/17/3/33381). 2017 for 4 year (£2.5 million). (Principal Investigator, Prof Andrew Baker).

Duration of dual anti-platelet therapy in acute coronary syndrome across Scotland. The DUAL-ACS2 Trial. BHF Clinical Study Grant (CS/17/4/32960). 2017 for 5 year (£630k). (Principal Investigator, Prof David Newby).

Refining the diagnosis of type 2 myocardial infarction. BHF Clinical Research Training Fellowship (FS/16/75/32533). 2016 for 3 years (£283k) for Dr Andrew Chapman.

High-sensitive cardiac troponin and coronary heart disease. BHF Butler Senior Clinical Research Fellowship (FS/16/14/32023). 2016 for 5 years (£1.2m).

Identification and characterisation of a vessel wall endothelial progenitor cell, and its potential for vascular regeneration. BHF Intermediate Research Fellowship (FS/16/4/31831). 2016 for 4 years (£540k).

High-sensitivity cardiac troponin on presentation to rule out myocardial infarction (HiSTORIC): A randomised controlled trial. BHF Project Grant (PG/15/51/31596). 2015 for 3 years (£272k)

BHF UK Cardiovascular Regenerative Medicine Centre Award (RM/13/2/30158). 2013 for 4 years (£2.5m).

Lipid mediators as predictors of nanoparticle-induced cardiovascular disease. BHF Special Project Grant (SP/15/8/31575). 2015 for 4 years (£538k).

Development of a clinical translational model of arterial injury and repair to assess vascular stem cell therapies. BHF Project Grant. 2013 for 3 years (£299k).

High-sensitive troponin in the evaluation of patients with acute coronary syndrome (HighSTEACS): A randomised controlled trial. BHF Special Project Grant (SP/12/10/29922). 2012 for 3 years (£702k)

>>79366

YAAKOV NAHMIAS

Professor and Director Center for Bioengineering at The Hebrew University of Jerualem, Israel

Prof. Yaakov “Koby” Nahmias is a bioengineer and innovator, whose breakthroughs ranged from the first 3D printing of cells to the first commercial human-on-chip technology. He is a Magna Cum Laude graduate of the Technion, Israel Institute of Technology, and is the founding director of the Grass Center for Bioengineering of the Hebrew University of Jerusalem. Nahmias is a recipient of a NIH career award, two European Research Council (ERC) grants, the Kaye Innovation Award and the prestigious Rappaport Prize in Biomedical Research. He is the first scientist outside Britain to win the Rosetrees Trust Prize. Nahmias is the co-founding director of BioDesign-Israel an entrepreneurship program that educated over 120 fellows, and launching 6 startup companies including Guide In Medical, CardioVia and Swiftduct. Nahmias is the founder and CSO of two biotechnology startups, including Tissue Dynamics that is developing a groundbreaking human-on-chip instruments for drug development, and the Tyson Foods-funded Future Meat Technologies focusing on the cost-effective production of cultured meat.

YORAM PALTI

Professor Emeritus Physiology and Biophysics Technion University, Israel; Founder and Chief Technology Officer Novocure, Israel

Professor Yoram Palti received his M.Sc., Ph.D. and M.D. from The Hebrew University Hadassah Medical School, Jerusalem. He was appointed an Associate Professor of Physiology at the University of Maryland School of Medicine in 1969 and an Assoc Prof. of Physiology and Biophysics at the Technion Medical School in 1971 and Full Prof. in 1976. Currently he is Prof. Emeritus at the Technion.

Palti served as the Head of the Dept. of Physiology & Biophysics (1971- 1991) and as the Head of the Rappaport Family Institute for Research in the Medical Sciences, the research arm of the Technion, from its establishment in 1982 till 1993.

Professor Palti has founded several startup companies, for example: Carmel Biosensors, Echosense, O2Cure, BG Guard and the highly successful Novocure that was established in 2000 and currently has a Cap value of over $20 Billion (NVCR). At NovoCure Palti served as Director through 2018 and serves as the company’s Chief Technology Officer to date.

>>79331

Baker back, lemme collect

>>79367

NINA RAWAL

Founder of Emerging Health Ventures, Stockholm, Sweden

Dr. Nina Rawal is the founder of Emerging Health Ventures. Previously, she headed the life science investment team at Industrifonden, a 600 million EUR venture capital fund. Previous experience also includes of Vice President, Strategy and Ventures at Gambro AB, and management consulting at Boston Consulting Group in Stockholm and New York. She serves on the boards of MedCap AB (publ) and Stockholms Sjukhem, a non-profit hospital and health care organization. She holds a PhD in Molecular Neurobiology, and a MSc in Biomedicine, both from the Karolinska Institute, including research work done at Columbia University in New York and at Hôpital la Salpêtrière in Paris.

Recognition for her work includes the selection as a Young Global Leader by the World Economic Forum and a '40 under 40 - European Young Leader' by Friends of Europe/Europanova.

GUR ROSHWALB

Partner at aMoon, Ra'anana, Israel

Dr. Gur Roshwalb is a Partner at aMoon, where he leads sourcing efforts, leads deals, manages the due diligence process, and sits on the board of AltruBio and Viracta Therapeutics, aMoon Growth portfolio companies. Beginning his career as a practicing physician, Gur understands the urgency driving the innovation in the healthcare industry. He moved to Israel in 2019 to work with aMoon to accelerate HealthTech advances into clinical practice. Gur has over 20 years of healthcare industry and finance experience. Prior to joining aMoon, he was CEO at several private and public biotech companies. Earlier, Gur was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. Gur started his finance career at Piper Jaffray, where he worked as a vice president and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, Gur was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he also served as Chief Resident. Gur obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business, and a B.A. from Columbia University.

NIELS SHARMAN

Investment Analyst at HTGF, High-Tech Gründerfonds, Bonn, Germany

Niels Sharman is an Investement Analyst within the Life Sciences team of HTGF. He holds a bachelor degree in biology from the Ludwig-Maximilians-University Munich and a master in management from the Technical University Munich. In the past he gained experience in the pharmaceutical industry and contributed to a biotech start-up.

MILDRED Z. SOLOMON

President at The Hastings Center, Garrison, New York USA

Mildred Z. Solomon, EdD is the President of The Hastings Center, the nation’s founding bioethics research institute, focused on examining the social and ethical implications of health and health care, science, and emerging biomedical technologies. She is also Professor (part-time) of Global Health and Social Medicine at Harvard Medical School, where she runs a Fellowship in Bioethics and has trained over 200 scientists, physicians and other kinds of professionals from across the United States and around the world. Dr. Solomon’s own research covers a broad spectrum of topics -- including, for example, the ethics of end-of-life care, organ transplantation, medical professionalism, and responsible conduct of research. She recently completed a two-year term on the World Economic Forum’s Global Futures Council on Technology, Values and Policy. She has served on committees of the National Academies of Sciences, Engineering and Medicine, on the US Secretary of Health and Human Services’ Advisory Committee on Organ Transplantation, and is currently a member of the Global Health Advisory Committee of the Open Society Foundations’ Public Health and Human Rights Programs. Dr. Solomon has over 70 academic publications in peer-reviewed journals and is also frequently cited in the mainstream media, including the Wall Street Journal, National Public Radio, New York Review of Books, The Daily Beast, Forbes, Science News, The Scientist and other outlets. A frequent public speaker, she has presented at Aspen Health, the New York Academy of Sciences, academic medical centers, and numerous public venues. Before leading The Hastings Center, she was Senior Director for Implementation Science at the Association of American Medical Colleges and before that, Vice President of Education Development Center, an independent research institute in Boston, MA. Dr. Solomon holds a B.A from Smith College and a doctorate in educational research methods from Harvard University.

>>79369

ANETTE STRÖH

Project Manager Digital Health and Scouting at BIH Digital Labs, Berlin, Germany

2007 Diploma Product Design, Bauhaus University Weimar

2010 MA Medical Design, Muthesius School of Arts, Kiel

2011-2015 Brand Strategist, f+d design studios, Hamburg

2015 Consultant, diffferent strategy consultancy, Berlin

2015-2017, Design Lead Participatory Health Unit , IXDS, Berlin

2017-2020, Service Design Lead, designit Germany, Berlin

since Dec 2020, Project Manager Digital Health and Scouting, Berlin Institute of Health, Berlin

ALEX WALDRON

CEO at Wellinks, New Haven, Connecticut, USA

Alex Waldron is Chief Executive Officer at Wellinks, a COPD-focused digital health company fueled by a mission to empower people in their pursuit to breathe freely. Wellinks’ lead asset is a digitally enabled and outcomes-driven holistic virtual care management solution for COPD, with a focus on reinventing respiratory care. The company’s expertise in COPD innovation began with the development and FDA 510(k) clearance of Flyp Nebulizer, the first truly pocket-portable nebulizer, allowing patients simple, convenient, and connected access to breathing treatments. Wellinks connects individuals and their caregivers through a suite of medical devices and intuitive software, enabling virtual COPD care management based on information that is real-time, accurate, and actionable.

Executive global bio/pharmaceutical business leader with 25+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.

JACKIE WARING

Founder & CEO at Investing Women Angels & AccelerateHER, Edinburgh, Founder & CEO at Investing Women Angels & AccelerateHER, Edinburgh, Scotland

Jackie Waring MA (Hons), DMS, DipM, MSc Founder & CEO, Investing Women Angels & AccelerateHER

Jackie is a pioneer of women angels ‘changing the face of angel investing’; bringing more women angels into Scotland’s dynamic angel investment community. An active and experienced angel investor herself; she established and leads Scotland’s all-female angel group Investing Women Angels whose members have invested over 80% of their funds in highly innovative female founded/co-founded companies.

Jackie is an entrepreneur with a passion for helping other entrepreneurs. It was this passion which inspired her to establish AccelerateHER; creating a channel and direct help for female founders going for scale. Publicly recognised by Scotland’s First Minister; she is a major player in shaping the ScotCanDo eco-system. The AccelerateHER Awards, workshops, mentoring and other support are achieving tangible impact; boosting the volume and investment in Scotland’s female-led companies. She has also nurtured strong international partnerships leading to regular AccelerateHER missions to Silicon Valley, Dubai, Berlin; and now Boston and New York in partnership with Founders Forum:

Jackie has previously run three companies, including 10 years CEO of a business/economic development organisation in Scotland. She has also been an external policy advisor to UK government; leading on the access to finance agenda for women entrepreneurs.

RICHARD YOUNG

Professor at Whitehead Institute/MIT, Cambridge, Massachusetts, USA

Richard Young is a Professor at the Whitehead Institute and MIT. Dr. Young studies gene regulation in health and disease and has mentored more than 100 graduate and postdoctoral students, many of whom now lead academic and commercial research programs and enterprises. Young has served as an advisor to the World Health Organization, the National Institutes of Health and numerous scientific societies and journals. His honors include Membership in the National Academy of Sciences and the National Academy of Medicine, and Scientific American has recognized him as one of the top 50 leaders in science, technology and business. He has founded and advised companies in the biotechnology and pharmaceutical industry, and currently serves on the boards of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics and Dewpoint Therapeutics. Young is also an aviator and holds a commercial pilot license.

>>79369

>World Economic Forum

BINGO

>>79353

quite rare

https://forebears.io/de/surnames/quandt

Total: 3,022

Frequency:1:26,640

>>79343

https://www.stiftung-charite.de/en/conferences/charite-entrepreneurship-summit/advisory-board

Advisory Board Members

IDA BEERHALTER

Spokeswoman, Summit Advisory Board & Co-Head, IOME

Ida Beerhalter is Co-Head of IOME, a private investment partnership of women principals from the Gulf region with its head office in Riyadh, KSA.

Additionally, Mrs Beerhalter also serves as Member of the Board, Trustee, Advisor and Expert to various for-profit and not-for-profit organizations around the globe (amongst others Astia, Auma Obama Foundation Sauti Kuu, Omnia Strategy, First Light Trust, Women Political Leaders (WPL) Global Forum, slavefreetrade.org, Professors Without Borders, Yunus Social Business, TBLI Group The Netherlands, Charité Foundation Summit Germany). She is specialized in a wide range of issues including investing & wealth management , entrepreneurship, social business & impact investment, gender inclusiveness, women empowerment, education, emerging markets and family governance and succession planning.

CHARLIE CAMERON

Senior Vice President, Business Development, Cooley

Charlie Cameron has over 25 years of business development, investing and management consulting experience in more than 30 countries. His experience ranges from working on strategy with Fortune 500 companies, to counseling emerging technology and life science companies, to venture investing. In addition, he mentors emerging companies, judges numerous business plan competitions and is a frequent speaker on innovation and entrepreneurship. He founded the Hub Angel Investment Group, which is on its fifth fund. He works with a plethora of entrepreneurs, innovators and investors in Europe, with special focus on DACH countries. Charlie is also Senior VP of Strategy at Cooley LLP, a global law firm with deep experience working with life science and tech companies and venture funds. He is on the board of the German American Business Council, Boston, the advisory board of the German Accelerator Life Science, and several other boards and advisory groups. During the past decade, Charlie has built a global network of entrepreneurs, investors, innovators, and others. He is a frequent speaker on panels and at forums related to venture capital and entrepreneurship. He has an MBA from MIT, an MPH from Harvard University, and a BA, Economics-honors, Phi Beta Kappa, from the University of Massachusetts.

>>79373

JOHN HALLINAN

Chief Development Officer, Danforth Advisors, Waltham, MA

JOHN HALLINAN John Hallinan joined Danforth Advisors in 2020 as the Chief Development Officer. John’s experience in the life sciences reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions. Prior to Danforth Advisors, John was the Chief Business Officer at MassBio and Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio—serving on the Economic Development Advisory Group and as co-chair of the Finance Committee & Entrepreneur’s University. Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the company’s healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading biopharma applications and enterprise solutions supplier. As Animation Technologies’ CFO, he guided the company’s first and second rounds of venture funding. John serves on the Advisory Board of the Charité BIH Entrepreneurship Summit and the Advisory Board of the Massachusetts Technology Transfer Center (MTTC), and proud to serve as a mentor in MassCONNECT, the premier mentoring program for early-stage companies and aspiring entrepreneurs.

JOANN HALPERN

Director, Hasso-Plattner-Institut, New York

Dr. Joann Halpern is the New York Director of the Hasso-Plattner-Institut für Digital Engineering (HPI) and an Adjunct Professor of International Education at New York University. Before joining HPI, Halpern lived in Cologne, Germany and helped to prepare a new, global university for accreditation. She moved to Cologne from New York City where she was Founding Director of the German Center for Research and Innovation (GCRI).

Prior to joining the GCRI, Dr. Halpern was Director of Academic Affairs and Senior Studies and Assistant Professor of International Education at Global College of Long Island University. She also co-founded Knowledge Transfer Beyond Boundaries, an NGO with projects in Cameroon, Nigeria, and Yemen. From 1996 to 2001, Halpern was Director of International Programs at Harz University of Applied Sciences in Wernigerode, Germany. She received her B.A. from Dartmouth College, her M.A. from Harvard University, and her Ph.D. from New York University. Dr. Halpern is a recipient of the Harvard Award for Distinction in Teaching as well as scholarships and fellowships from the Fulbright Association, German Academic Exchange Service, Robert Bosch Foundation, and the National Endowment for the Humanities. She serves on the advisory boards of the Charité Entrepreneurship Summit, German Accelerator, Technical University of Dortmund, University Alliance Ruhr, and Virtual Enterprises International.

>>79374

ANULA JAYASURIYA

Founder, eXXclaim Capital, EILSF

Anula Jayasuriya is an experienced health care and Life Sciences executive and investor. Anula’s expertise consists of a unique combination of business, basic science and medical knowledge.

Recognizing the growing yet under-invested opportunity in Women’s Health, in 2013 Anula launched eXXclaim Capital, focused on catalyzing innovation, entrepreneurship and investment in this field and has already made several investments. In 2006 Anula co-founded the “Evolvence India Life Science Fund” (EILSF), to make investments in pharmaceutical, biotechnology, medical device and contract services companies based in India. EILSF has garnered three successful exits to date and India Life Science 11 has had its first close.

She was previously a partner with Skyline Ventures in Palo Alto, and prior to that with the German – US venture capital firm TVM, in San Francisco. Her prior positions include VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche for opportunistic infections in AIDS and Transplantation. Anula received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and received an MBA with distinction from Harvard Business School. Anula also has a M. Phil. in pharmacology from the University of Cambridge, in England. Anula sits on the boards of Ocimum BioSolutions, and MapMyGenome, Hyderabad and nVision, San Francisco. She was previously a board member of Health Care Global which was exited to Temasek, Lipomics which was acquired by Tethys and Triesta BioSciences which was acquired by Health Care Global. She also serves on several non-profit boards, including Astia, EPPIC, and The Gruter Institute for Law and Behavioral Research.

MARKUS MÜSCHENICH

Co-Founder & Managing Partner, Flying Health Incubator

Markus Müschenich is a board certified pediatrician and has a degree in Public Health. He is the founder of ConceptHealth, a think tank with longterm expertise in strategic business development based on health care's future foresight analysis. After more than ten years membership of executive boards in private and nonprofit hospital companies, Dr. Müschenich co-founded FLYING HEALTH a German company builder and business developer for health startups. FLYING HEALTH partners with founders, connects geeks and healthcare professionals and supports R&D for innovative products and services gaining market access. Dr. Müschenich is member of the board of directors of the German Association for Internet Medicine.

ANNIKA PIERSON

Annika Pierson, Co-Founder & Chief Operating Officer, Advise Connect Inspire

Through various roles in the German and the US healthcare industries, Annika has extensive experience building strong global networks by bringing together investors, entrepreneurs, and senior industry executives. As Chief Operating Officer of ACI, she facilitates the successful US market entry of emerging companies from Europe and connects US-based startups with European investors and industry groups. Prior to joining the German Accelerator Life Sciences (GALS) and founding ACI in Cambridge, MA, Annika headed the innovation and entrepreneurship programs of Charité Foundation in Berlin, including the highly successful international healthcare industry conference, Charité Entrepreneurship Summit.

JOACHIM RAUTTER

Co-Founder, Peppermint VenturePartners

Joachim Rautter is a co-founder of Peppermint VenturePartners and Managing Partner of Peppermint Charité Biomedical Fund.

Prior to the launch of Peppermint VenturePartners, he was Investment Director at Peppermint Holding GmbH. There he was responsible for the investment activities of the Peppermint Venture Capital Fund. He has over 15 years of experience in the venture capital industry and was Chairman of the Supervisory Board of Scienion AG, as well as Chairman of the Advisory Board of JADO Technologies GmbH and Innolume GmbH. He is currently Chairman of the Board of CEVEC Pharmaceuticals GmbH and CellAct Pharma GmbH, and also serves on the Board of CryoTherapeutics GmbH and Labfolder GmbH.

Prior to joining Peppermint, he guided innovative start-ups in the field of start-up financing and entrepreneurial development. In addition, he was involved in key functions in the design and implementation of regional innovation strategies.

Joachim Rautter has a degree in physics and completed his PhD at the Max Volmer Institute for Biophysical Chemistry at the Technical University of Berlin.

#483

>>79288, >>79303, >>79312, >>79313, >>79315, >>79316, >>79341, >>79349, >>79349, Eyez to the skyz

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79337, >>79338, >>79342, >>79343, >>79346, >>79347, >>79350, >>79351, >>79352, >>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371, >>79373, >>79374, >>79375, Moar QUANT FAMILY

>>79336 ITALY : SOON Unvaccinated BANNED from Voting

>>79334, >>79335 ‘Unnecessary, misleading, catastrophic’: Senior European physicians co-author expert statement on COVID vaccine for children

>>79333 Senior US diplomat Sherman speaks with Myanmar shadow government

>>79330 Mexico Sues Smith & Wesson and Glock Over Smuggled Firearms

>>79329 The SARS-CoV-2 as an instrumental trigger of autoimmunity

>>79328 Our office recently fought a similar legal challenge to Arizona's election integrity measures and won in the #SCOTUS case 𝑩𝒓𝒏𝒐𝒗𝒊𝒄𝒉 𝒗. 𝑫𝑵𝑪.

>>79326 45 talking congressional wins

>>79314, >>79317 @ORNL, which just got a shipment of advanced fuel rods that went through testing in a commercial reactor.

>>79312 Boeing 737 Max heads to China for key test to end flight ban

>>79309 This is the actual results of the Elections. H/T Scooby Snacks.

>>79307 Baker Hughes Company sold by General Electric Co.: $1.254B-August 3

>>79306 Rebels were, "too powerful to be suppressed by the powers vested in the Marshal of that District." Washington called out the state militias.

>>79305 Introducing wtube.org

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

#483

seems diggz should be better organized/labeled

digger lemme know

czech em

Mike Lindell: “This is a spiritual battle of epic proportions…the evil is revealing itself.”

“This has been the biggest coverup in the biggest crime ever.”

“We’re going to air 72 hours straight, starting at 9 am the morning of the 10th.”

“This isn’t about Donald Trump. This is an attack on our country by China.”

“They’re trying to destroy as much of our country…They know the truth is coming out.”

https://protrumpnews.com/mike-lindell-we-have-everything/

>>79350

could you possible break my followup post on Polly out, because it gives an overview? something like this

>>79350, >>79351 Amazing Polly - followup on ENTRUST/Quandts

>>79376

how about a bun for details on Quandts?

>>79378

there are also multiple archived ones

• Foundation Charite, which is separated in speakers 2021 and advisory board, board of trustees, and everything else

• then there is this Jasmin QUANDT Scientist at BioNTech

Bundling everything together is not good imo

>>79379

whatever you think, I don't see how the diggz are divided, you do that with descriptions labels

>>79379

Why though? Simply split them up accordingly.

We don't know for sure if Jasmin Quandt is part of that family, but it's highly likely.

https://en.wikipedia.org/wiki/Member_states_of_the_Commonwealth_of_Nations

The Commonwealth of Nations is a voluntary association of 54 sovereign states. Nearly all of them are former British colonies or dependencies of those colonies.

No one government in the Commonwealth exercises power over the others, as is the case in a political union. Rather, the Commonwealth is an international organization in which countries with diverse social, political, and economic backgrounds are regarded as equal in status, and cooperate within a framework of common values and goals, as outlined in the Singapore Declaration issued in 1971.[1] Such common values and goals include the promotion of democracy, human rights, good governance, the rule of law, individual liberty, equality before the law, free trade, multilateralism, and world peace, which are promoted through multilateral projects and meetings, such as the Commonwealth Games, held once every four years.[2]

The symbol of this free association is Queen Elizabeth II, who serves as the Head of the Commonwealth. This position, however, does not imbue her with any political or executive power over any Commonwealth member states; the position is purely symbolic, and it is the Commonwealth Secretary-General who is the chief executive of the Commonwealth.[3]

The Commonwealth was first officially formed in 1926 when the Balfour Declaration of the Imperial Conference recognized the full sovereignty of dominions. Known as the "British Commonwealth", the original members were the United Kingdom, Canada, Australia, New Zealand, South Africa, Irish Free State, and Newfoundland. It was re-stated by the 1930 conference and incorporated in the Statute of Westminster the following year (although Australia and New Zealand did not adopt the statute until 1942 and 1947 respectively).[4] In 1949, the London Declaration marked the birth of the modern Commonwealth and the adoption of its present name.[5] The newest member is Rwanda, which joined on 29 November 2009.[6] The 54 members have a combined population of 2.4 billion, almost a third of the Earth's population, of whom 1.21 billion live in India, and 95% live in Asia and Africa combined.[7]

Currently, sixteen of the 54 member states are Commonwealth realms, with the Head of the Commonwealth as their heads of state, five others are monarchies with their own individual monarchs (Brunei, Eswatini, Lesotho, Malaysia and Tonga), and the rest are republics. The Republic of Ireland (as of 1949 according to the Commonwealth; 1936 according to Irish government) and Zimbabwe (2003) are former members of the Commonwealth. South Africa, Pakistan, The Gambia, and the Maldives left and later rejoined the Commonwealth, and Zimbabwe has formally applied to rejoin.

>>79344

i'll make a summary bun, that ok?

>>79384

buns not good, because images are only archived for posts that are directly notabled (and also when they are large enough resolution-wise).

Just split it up directly.

When Q uses all caps

It is usually because the word is an acronym

And each line of a drop is potentially unrelated

Because Q mixes subjects together

So you really have to think

And to dig to find the connections

In these two, I think BIG connects to the images

Not to the other lines in the drop

>>79386

When Q uses all caps

It is usually because the word is an acronym

And each line of a drop is potentially unrelated

Because Q mixes subjects together

So you really have to think

And to dig to find the connections

In these two, I think BIG connects to the images

Not to the other lines in the drop

Two AWOL Texas Democrats Who Fled to DC to Block GOP Voting Bills Go Missing – Reportedly Vacationing in Portugal

https://www.thegatewaypundit.com/2021/08/two-awol-texas-democrats-fled-dc-block-gop-voting-bills-go-missing-reportedly-vacationing-portugal/

>>79337

Rob QUANDT (Ex-Associate Creative Director Pfizer/AstraZeneca)

https://www.linkedin.com/in/rob-quandt-21229b34/

https://archive.is/zTh6s

Associate Creative Director at WILDTYPE

Brooklyn, New York, United States

About

Therapeutic categories: Aesthetics, Allergy, Alzheimer’s, Assisted reproduction, Asthma, Cardiovascular, COPD, Dermatology, Diabtetes, Gastrointestinal, Hyperuricemia/gout, Infection, Oncology, Pain management, Rheumatoid arthritis, Women’s health/gyn, Vaccines

Experience

WILDTYPE, a TBWA\WorldHealth Company

Associate Creative Director

Company Name

WILDTYPE, a TBWA\WorldHealth Company ·Full-time

Dates Employed 2018 – Present

Employment Duration ·3 yrs

Location Greater New York City Area

Keytruda (oncology) - Merck

Welireg (VHL disease) - Merck

Ontruzant (oncology) - Merck Biosimilars

Aybintio (oncology) - Merck Biosimilars

Freelance Various

Freelance Associate Creative Director

Company Name

Freelance Various

Dates Employed 2010 – Present

Employment Duration ·11 yrs

Location Greater New York City Area

MRM/McCann - Shingrix

CDM NY - Xifaxan

Biolumina - Zometa

Cementbloc - Cimzia

DraftFCB - Amyvid, Solanezumab

Harison & Starr - Genetech Bio-oncology

StrikeforceNYC - Paragard

Havas Life - Meade Johnson, Milprosa, Restylane, Dysport, Walgreens, Biogen

Havas Lynx - Sarilumab

Havas Life Metro - Admelog, Soliqua

Digitas Health - Linzess, Eliquis

Ogilvy Commonhealth - Striverdi

Grey Group

Associate Creative Director

Company Name

Grey Group ·Freelance

Dates Employed 2014 – 2018

Employment Duration ·4 yrs

Location Greater New York City Area

Basaglar (T2 diabetes) - Eli Lilly

Olumiant (RA) - Eli Lilly

Taltz (psoriatic arthritis) - Eli Lilly

Xalkori (oncology) - Pfizer

BGB Group

Associate Creative Director

Company Name

BGB Group ·Freelance

Dates Employed 2012 – 2014

Employment Duration ·2 yrs

Location New York, United States

Movantik (opioid-induced constipation) - AstraZeneca

Opdivo (oncology) - AstraZeneca

Ogilvy & Mather

Associate Creative Director

Company Name

Ogilvy & Mather ·Full-time

Dates Employed 2007 – 2010

Employment Duration ·3 yrs

Location Greater New York City Area

Flibanserin (women's health) - Boehringer

Tygacil (antibiotic) - Wyeth

Relistor (mu-opioid inhibitor) - Wyeth

Qlaira (contraception) - Bayer

Natrelle (aesthetics) - Allergan

Juvederm (aesthetics) - Allergan

Latisse (aesthetics) - Allergan

SAATCHI & SAATCHI HEALTHCARE COMMUNICATIONS, INC.

Copy Supervisor

Company Name

SAATCHI & SAATCHI HEALTHCARE COMMUNICATIONS, INC. ·Full-time

Dates Employed 2005 – 2007

Employment Duration ·2 yrs

Location Greater New York City Area

Enbrel (RA) - Amgen

Ambien (insomnia) - Sanofi

Ambien CR (insomnia) - Sanofi

Elitek (hyperuricemia) - Sanofi

Education

Fordham University - Graduate School of Business Administration

Fordham University - Graduate School of Business Administration

Degree Name Master of Business Administration - MBA,

Field Of Study Finance

Dates attended or expected graduation 1995 – 1998

Providence College

Providence College

Degree Name BS,

Field Of Study Marketing

Dates attended or expected graduation 1989 – 1993

New York University

New York University

Field Of Study Digital Media

Dates attended or expected graduation 1999 – 2000

Universität Salzburg

Universität Salzburg

Dates attended or expected graduation 1994 – 1994

Skills & endorsements

Creative Strategy

See 27 endorsements for Creative Strategy ·27

person

Endorsed by Davar Azarbeygui and 4 others who are highly skilled at this

company

Endorsed by 3 of Rob’s colleagues at Grey Group

Interactive Advertising

See 21 endorsements for Interactive Advertising ·21

person

Endorsed by Andrew Bartel and 1 other who is highly skilled at this

company

Endorsed by 2 of Rob’s colleagues at Grey Group

Advertising

See 17 endorsements for Advertising ·17

person

Endorsed by Davar Azarbeygui and 5 others who are highly skilled at this

company

Endorsed by 2 of Rob’s colleagues at Grey Group

>>79384

Oh and that Drosten female that got 250.000 EUR from that Quandt-Foundation, that's ALSO separate and it's actually very very important.

>>79389

Can a BV please fix my formatting at the start? 2 "==" are missing.

>>79388

i can't afford to go to portugal.

Despite Deadly Results the FDA will Fast Track Pfizer COVID Vaccine Approval by Early Sept. — Will Allow States and Businesses to Begin their Forced Vaccinations

https://www.thegatewaypundit.com/2021/08/despite-deadly-results-fda-will-fast-track-pfizer-covid-vaccine-approval-early-sept-will-allow-states-businesses-begin-forced-vaccinations/

>>79392

show me exactly what you need done

>>79395

Formatting of this:

Rob QUANDT (Ex-Associate Creative Director Pfizer/AstraZeneca)==

right at the start of the post.

>>79376

>>79385

Organized into categories, can be a bun or just put in notes

plz ck for accuracy

QUANT DIG

>>79337, >>79350, >>79351 Moar Quandt fam - NEW Amazing Polly vid plus notes

>>79338, >>79339 Sandra Ciesek

>>79343, >>79343, >>79352 Foundation Charite

>>79346, >>79347 Jasmin Quandt

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite conference - 2021 speakers

>>79372 How common is the name Quandt? Pretty rare

>>79373, 79374, 7937 Charite Advisory Board Members

>>79397

REVISED

>>79376

>>79385

Organized into categories, can be a bun or just put in notes

plz ck for accuracy

QUANT DIG

>>79337, >>79350 (You), >>79351 (You) Moar Quandt fam - NEW Amazing Polly vid plus notes

>>79338, >>79339 Sandra Ciesek

>>79343, >>79343, >>79352 Foundation Charite

>>79346, >>79347 Jasmin Quandt

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite conference - 2021 speakers

>>79372 How common is the name Quandt? Pretty rare

>>79373, >>79374, 79375 Charite Advisory Board Members

>>79396

>>79395

i see it cakes. logging in nao.

REFRESH

>>79397

Please add Jasmin Quandt - "Scientst at BioNTech, involved in BNT162b2 gene therapy development"

Also add to Sandra Ciesek - "in a team with PCR-test-Drosten, received 250.000 EUR in March from Charite Foundation / Quandt"

Foundation Charite - "2 Quandt family members on the board of trustees"

Charite Advisory Board Members -Charité Foundation Advisory Board Members

QUANDT DIG

>>79337, >>79350, >>79351 Moar Quandt fam - NEW Amazing Polly vid plus notes

>>79338, >>79339 Sandra Ciesek ( PCR-test-Drosten, rec'd 250.000 EUR from Foundation Charite

>>79343, >>79352 Foundation Charite (2 Quandt fam members on the board)

>>79346, >>79347 Jasmin Quandt - Scientst at BioNTech, involved in BNT162b2 gene therapy development

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite conference - 2021 speakers

>>79372 How common is the name Quandt in Germany? Pretty rare

>>79373, >>79374, >>79375 Charité Foundation Advisory Board Members

>>79373, >>79374, >>79375 Charite Advisory Board Members

>>79389 Rob QUANDT (Ex-Associate Creative Director Pfizer/AstraZeneca)

>>79401

aslo Rob QUANDT has to be added too, I just posted that one

"(Ex-Associate Creative Director Pfizer/AstraZeneca)"

>>79401

hang on

will just edit the post

>>79402

>How common is the name Quandt? Pretty rare

add: "in Germany"!

It's most common in Germany compared to the rest of the world.

#483

>>79288, >>79303, >>79312, >>79313, >>79315, >>79316, >>79341, >>79349, >>79349, Eyez to the skyz

>>79373, >>79374, >>79375 Charite Advisory Board Members

>>79372 How common is the name Quandt? Pretty rare

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite conference - 2021 speakers

>>79346, >>79347 Jasmin Quandt

>>79343, >>79343, >>79352 Foundation Charite

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79338, >>79339 Sandra Ciesek

>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Quandts

>>79336 ITALY : SOON Unvaccinated BANNED from Voting

>>79334, >>79335 ‘Unnecessary, misleading, catastrophic’: Senior European physicians co-author expert statement on COVID vaccine for children

>>79333 Senior US diplomat Sherman speaks with Myanmar shadow government

>>79330 Mexico Sues Smith & Wesson and Glock Over Smuggled Firearms

>>79329 The SARS-CoV-2 as an instrumental trigger of autoimmunity

>>79328 Our office recently fought a similar legal challenge to Arizona's election integrity measures and won in the #SCOTUS case 𝑩𝒓𝒏𝒐𝒗𝒊𝒄𝒉 𝒗. 𝑫𝑵𝑪.

>>79326 45 talking congressional wins

>>79314, >>79317 @ORNL, which just got a shipment of advanced fuel rods that went through testing in a commercial reactor.

>>79312 Boeing 737 Max heads to China for key test to end flight ban

>>79309 This is the actual results of the Elections. H/T Scooby Snacks.

>>79307 Baker Hughes Company sold by General Electric Co.: $1.254B-August 3

>>79306 Rebels were, "too powerful to be suppressed by the powers vested in the Marshal of that District." Washington called out the state militias.

>>79305 Introducing wtube.org

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

#483

>>79399

bless you

>>79407

I edited this based on anon feedback

>>79402

PLZ REFRESH

sorry for confusing, complicated

>>79409

You decide, you da baker, your call

we diggers do our best

>>79405

tx for getting it all here b4 they do a quick scrub

>>79409

>I edited this based on anon feedback

wasn't really edited??!!

Let me edit these few

>>79407

sore fingers, thinking to get off for a while

u ok?

Updated:

>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Family Quandts

>>79373, >>79374, >>79375 Charite Foundation Advisory Board Members

>>79372 How common is the name Quandt in Germany? Pretty rare

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite Foundation conference - 2021 speakers

>>79346, >>79347 Jasmin Quandt - Scientist at BioNTech, directly involved in BNT162b2

>>79389 Rob QUANDT (Associate Creative Director at WILDTYPE, Ex-Associate Creative Director Pfizer/AstraZeneca)

>>79343, >>79343, >>79352 Foundation Charite site

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79338, >>79339 Sandra Ciesek - involved w/ PCR-Test-Drosten, received a grant of 250.000 EUR from Charite Foundation/Johanna-Quandt-Foundation in March 2020

Please verify

DETROIT CRACK PRICES ARE TOO DAMN HIGH

>>79413

>involved w/ PCR-Test-Drosten

add:

"found out in February that there would be asymtomatic individuals carrying and spreading the coronavirus"

MOST IMPORTANT

>>79412

I'm fine

diggerz spergin but OK

they've not noticed I stack my notable the other way yet

kek

Updated:

>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Family Quandts

>>79373, >>79374, >>79375 Charite Foundation Advisory Board Members

>>79372 How common is the name Quandt in Germany? Pretty rare

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite Foundation conference - 2021 speakers

>>79346, >>79347 Jasmin Quandt - Scientist at BioNTech, directly involved in BNT162b2

>>79389 Rob QUANDT (Associate Creative Director at WILDTYPE, Ex-Associate Creative Director Pfizer/AstraZeneca)

>>79343, >>79343, >>79352 Foundation Charite site

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79338, >>79339 Sandra Ciesek - involved w/ PCR-Test-Drosten, found out in February that there would be asymtomatic individuals carrying and spreading the coronavirus, received a grant of 250.000 EUR from Charite Foundation/Quandts

>>79416

>diggerz spergin

>>79408

#483

>>79288, >>79303, >>79312, >>79313, >>79315, >>79316, >>79341, >>79349, >>79349, Eyez to the skyz

>>79337, >>79350, >>79351 Amazing Polly - followup on ENTRUST/Family Quandts

>>79373, >>79374, >>79375 Charite Foundation Advisory Board Members

>>79372 How common is the name Quandt in Germany? Pretty rare

>>79354, >>79355, >>79356, >>79357, >>79358, >>79359, >>79360, >>79361, >>79362, >>79363, >>79364, >>79365, >>79366, >>79367, >>79369, >>79370, >>79371 Charite Foundation conference - 2021 speakers

>>79346, >>79347 Jasmin Quandt - Scientist at BioNTech, directly involved in BNT162b2

>>79389 Rob QUANDT (Associate Creative Director at WILDTYPE, Ex-Associate Creative Director Pfizer/AstraZeneca)

>>79343, >>79343, >>79352 Foundation Charite site

>>79340 Russia Captures No. 2 Rank Among Foreign Oil Suppliers to U.S.

>>79338, >>79339 Sandra Ciesek - involved w/ PCR-Test-Drosten, found out in February that there would be asymtomatic individuals carrying and spreading the coronavirus, received a grant of 250.000 EUR from Charite Foundation/Quandts

>>79336 ITALY : SOON Unvaccinated BANNED from Voting

>>79334, >>79335 ‘Unnecessary, misleading, catastrophic’: Senior European physicians co-author expert statement on COVID vaccine for children

>>79333 Senior US diplomat Sherman speaks with Myanmar shadow government

>>79330 Mexico Sues Smith & Wesson and Glock Over Smuggled Firearms

>>79329 The SARS-CoV-2 as an instrumental trigger of autoimmunity

>>79328 Our office recently fought a similar legal challenge to Arizona's election integrity measures and won in the #SCOTUS case 𝑩𝒓𝒏𝒐𝒗𝒊𝒄𝒉 𝒗. 𝑫𝑵𝑪.

>>79326 45 talking congressional wins

>>79314, >>79317 @ORNL, which just got a shipment of advanced fuel rods that went through testing in a commercial reactor.

>>79312 Boeing 737 Max heads to China for key test to end flight ban

>>79309 This is the actual results of the Elections. H/T Scooby Snacks.

>>79307 Baker Hughes Company sold by General Electric Co.: $1.254B-August 3

>>79306 Rebels were, "too powerful to be suppressed by the powers vested in the Marshal of that District." Washington called out the state militias.

>>79305 Introducing wtube.org

>>79299 Fed's Clarida backs raising interest rates in 2023

>>79282 Vote to Remove Gavin Newsom Within Margin of Error; Hispanics Favor Recall

#483

all guud?

bake is set

>>79418

LMAO

guud think I got some rest and food huh

>>79411

it was editied if you refresh, although i dropped a parenthesis i'm afraid - just not changed by baker bc he was busy posting notes

this happens often, espec when a lot of info comes in at once

>>79420

blessings cakes

overtime pay due

>>79423

boop on da nose guud enough yo

grin

>>79423

feelz bad on dis end but been wurkfagg'n like a retard all day today.

>>79416

>sperging

well, you're right bout dat

dat's me for shure

concentrating one one thing, ignore another

apologies

>>79426

no problem

kekkin hard

just not the OCD idjit type

muh sides

lemme know if it's guud so I can bake

lord have mercy

Freshness

>>79428

>>79428

>>79428

>>79427

there's a dup here but no biggie

>>79343, >>79343, >>79352 Foundation Charite site